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Abstract 
 
The tumour microenvironment is composed of haematopoietic and stromal cell types 
that interact dynamically with tumour cells, thereby impacting on cancer development and 
progression. The recent realization that infiltrating myeloid cells display pro-tumour 
features is reflected in the increase in myeloid-derived suppressor cells in the blood of 
cancer patients, which is associated with bad prognosis. Moreover, in mouse models, the 
depletion of pro-tumour myeloid cells (PTMc) inhibits tumour growth and reduces the level 
of immunosuppression in the tumour microenvironment, thus releasing the anti-tumour 
activities of CD4+ and CD8+ T lymphocytes. 
To date, available strategies to manipulate PTMc include ablation (via antibody 
depletion or signalling blockade of myeloid cell survival factors) or inhibition of their pro-
tumour features. However, myeloid cells can undergo anti-tumour programming in 
response to stimulating agents like tissue damage signals, TLR and costimulatory 
receptor agonists. Polarized anti-tumour myeloid cells (ATMc) display tumoricidal 
functions and efficiently produce inflammatory cytokines, such as TNF-α, IFN-γ, IL-12 and 
enzymes like iNOS, while expressing low levels of T cell suppressive cytokines such as 
IL-10. ATMc are responsible for the priming of CTLs thus inducing tumour regression. 
Despite these findings, information characterizing anti-tumour features, functions, 
phenotype and transcriptional program of ATMc are critically lacking. Consequently, this 
project aimed at developing novel approaches to “reprogram” myeloid cells into ATMc in 
vivo during tumour responses and characterize their anti-tumour features.  
In this report we successfully demonstrate that myeloid cells can be induced to 
perform anti-tumour functions upon selective stimulation in vivo. In the orthotopic E0771 
mammary tumour model, injection of TLR3 ligand dsRNA and agonist anti-CD40 mAb 
stimulated macrophages to produce anti-tumour cytokines and enzymes. We defined anti-
tumour macrophages as CD11b+F4/80+Ly6C(+/-) cells that co-produced TNF-α and IL-
1β. Our data suggest a crosstalk between macrophages and CD8+ T cells, promoting 
potent anti-tumour immune responses and leading to tumour complete eradication in 90% 
of the treated animals. This approach provides a solid platform to question whether 
different TLR agonists may trigger functional diversification of ATMc of various lineages 
such as neutrophils. Our findings open the way to dissecting the transcriptional 
program(s) that operate in ATMc, aiming at new strategies to manipulate MC in the 
context of cancer. 
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Resumo 
 
O microambiente tumoral é composto por diversos tipos de células como as 
hematopoéticas ou do estroma que interagem com células tumorais, contribuindo para o 
desenvolvimento e crescimento do tumor. Recentemente, vários estudos têm 
demonstrado que as células mielóides podem apresentar funções pró-tumorais e que a 
sua presença no sangue de pacientes com cancro está associada a um mau prognóstico. 
Em modelos de ratinho, a eliminação de células mielóides com funções pró-tumorais 
(PTMc) inibe o crescimento tumoral e aumenta a atividade anti-tumoral dos linfócitos T 
CD4+ e CD8+. 
Até à data, as estratégias disponíveis para a manipulação de células mielóides 
passam pela depleção, através de anticorpos ou inibição de vias de sinalização, ou pelo 
bloqueio das suas características pró-tumorais. Todavia, as células mielóides podem 
adquirir funções anti-tumorais em resposta a sinais de dano, ligandos de recetores de Toll 
(TLR) e moléculas co-estimuladoras. Deste modo, as células mielóides polarizadas para 
um fenótipo anti-tumoral (ATMc) apresentam funções tumoricidas produzindo citocinas 
inflamatórias como o TNF-α, IFN-γ, IL-12 e enzimas como o iNOS e expressando menor 
quantidade de citocinas supressoras de células T como a IL-10. Assim, as ATMc ativam 
células T citotóxicas (CTLs) que, por sua vez, eliminam células tumorais. Apesar destas 
descobertas, informações sobre as características, funções e fenótipo das ATMc são 
ainda muito escassas. Deste modo, o nosso projeto teve como objetivo desenvolver 
novas abordagens que permitam a manipulação das células mieloides in vivo durante 
respostas tumorais, caracterizando as suas funções anti-tumorais.  
Neste estudo demonstrámos com sucesso que as células mielóides podem ser 
estimuladas a apresentar funções anti-tumorais in vivo. No nosso modelo ortotópico 
E0771 de células tumorais mamárias de ratinho, a injeção intra-tumoral do ligando 
dsRNA do TLR3 e do anticorpo agonista monoclonal anti-CD40, estimulou a produção de 
citocinas e enzimas anti-tumorais por macrófagos. Por conseguinte, definimos que os 
macrófagos anti-tumorais expressam os marcadores CD11b+F4/80+Ly6C(+/-) e que 
produzem TNF-α e IL-1β. Os nossos dados sugerem um crosstalk entre macrófagos e 
células T CD8+, gerando uma potente resposta imune anti-tumoral responsável pela 
completa erradicação do tumor em 90% dos animais tratados. Esta abordagem oferece 
um ponto de partida para o estudo de outros agonistas de TLR que estimulem funções 
anti-tumorais em diferentes linhagens de células mielóides como os neutrófilos. Os 
nossos resultados são promissores e permitem aspirar à descoberta dos programas de 
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transcrição responsáveis pela formação de células mielóides anti-tumorais (ATMc), 
fornecendo informações para a sua melhor manipulação no contexto tumoral. 
Palavras-chaves: Células mielóides, agonistas de TLR, funções anti-tumorais, modelo 
ortotópico de células tumorais mamárias de ratinho 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XII 
 
Table of Contents 
 
Agradecimentos…………………………………………………………………………….……II 
Abbreviations List…………………………………………………………………....…….....…IV 
Abstract…………………………………………………………………………….………...…..VIII 
Resumo……………………………………………………………………….…….....………....X 
Table of Contents ……………………………………………………………….…...……….…XII 
Introduction…………………………………………………………………………..….………...2 
1. The immune system and its immune cell functions……………………………...........2 
2. Myeloid cells lineages and functions in immunity………………………………….......5 
2.1. Myeloid cells lineages and functions………………………………..….……..5 
2.2. Monocyte differentiation and functions……………………………..…………6 
2.3. Macrophage ontogeny…………………………………………….…….….......6 
2.4. Macrophage functions during immune responses…………….…….…........7 
2.5. Granulocytes origin and functions during immune response……….….......8 
2.6. Dendritic cells ontogeny and functions during immune response……...….9 
3. Macrophage polarization during inflammation……………………………………...….10 
3.1. Macrophage polarization (M1 vs M2)…………………………………………10 
4. Immune cells control tumour development and growth………………………………11 
5. Cancer Immunotherapy……………………………………………………………...…..14 
5.1. Adoptive T cell transfer therapy…………………………………………........14 
5.2. Immune checkpoint inhibitors………………………………………………….15 
5.3. Vaccination therapies………………………………………………………......15 
6. Tumour cells manipulate immune cells……………...…………………………………16 
6.1. Tumour microenvironment……………………………………………………..16 
6.2. Tumour manipulation of immune cells………………………………………..17 
6.3. MDSC infiltrate tumour and differentiate into tumour-associated 
macrophages and neutrophils ………………………………………………...17 
6.4. Tumour-associated macrophages………………………………………...…..18 
6.5. Tumour-associated neutrophils………………………………………......…...19 
6.6. Different tumour types have different infiltrative myeloid cells…………..…19 
6.7. Myeloid cells are anti-tumour early in tumour development and become 
pro-tumour at a later stage of tumour progression……………………..…...20 
XIII 
 
7. Myeloid cells can be reprogrammed to have anti-tumour functions…………..…...21 
Objectives…………………………………………………………..…………………….….…..24 
Methods…………………………………………………………….………….………….....…..25 
1. Mice……………………………………………………………………………….…...…25 
2. Cell lines and tumour models………………………………………….……...…........25 
3. In vivo tumour transplantation………………………………………………..……..…25 
4. In vivo depletion of cell lineages…………………………………………….……...…26 
5. Flow Cytometry analysis……………………………………………………..….….….26 
6. In vitro assay…………………………………………………………………...………..28 
7. Statistical analysis…………………………………………………….………..…....…28 
Results……………………………………………………………………………..……….…….29 
1. TLR3 ligand and anti-CD40 induced tumour remission in vivo…………...…….…29 
2. TLR3 ligand and anti-CD40 did not affect the proliferation of E0771 tumour cell line 
in vitro………………………………………………………………………………..…..30 
3. Myeloid cells accumulate in the blood during tumour progression………….........31 
4. TLR3 ligand and anti-CD40 changed the composition of tumour-infiltrating myeloid 
cells……………………………………………………………………………….…..….32 
5. TLR3 ligand and anti-CD40 decreased the percentage of PD-L1high myeloid cells 
in the tumour………………………………………………………………………........34 
6. Macrophages produce TNF-α, iNOS and IL-1β in response to TLR3 ligand and 
anti-CD4…………………………………………………………………………..…......35 
7. Macrophages are required for tumour eradication, being target of TLR3 ligand and 
anti-CD40 treatment……………………………………………………………….…...39 
8. TLR3 ligand and anti-CD40 induced an increase in CD4+ and CD8+ T cell 
infiltrate………………………………………………………………………………......41 
9. TLR3 ligand and anti-CD40 induced a reduction of tumour-infiltrating exhausted 
CD8+ T cells and an increase of anti-tumour CD8+ T cell effectors……………...43 
10. CD8+ T cells, not CD4+ T cells, are required for tumour eradication upon TLR3 
ligand and anti-CD40 treatment……………………………………………………….45 
Discussion……………………………………………………………………………………......47 
1. Limitations…………………………………………………………………………….….47 
1.1. Orthotopic model………………………………………………………...….47 
1.2. Caliper tumour measurement………………………………….....….…....48 
XIV 
 
2. Possible scenarios of ATMc-treatment action on MC, leading to CD8+ T 
lymphocyte mediated tumour eradication..……………… …………………....…...48 
2.1. TLR3 ligand signalling pathway responsible for anti-tumour macrophage 
activation.………………………...……………………...……….….……..49 
2.2. Macrophage production of TNF-α, iNOS and IL-1β can promote CD8+ T 
lymphocyte activation………..…………………………………….……...50 
a) Direct action on CD8+ T cells..……………………………….…….…...50 
b) Indirect action on CD8+ T cells…….………………………………...….52 
2.3. Other findings that could be exploited………………………………......53 
 
3. Long term goal of our studies…………………………………………………….…..54 
4. Implications of our findings…………………………………………………………...55 
Supplementary figures……………………………………………………………………..…..56 
References……………………………………………………………………………………...60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Introduction 
 
1. The immune system and its immune cell functions 
The immune system is composed of several cell types with specialized roles in 
defending against infections and transformed cells (Nicholson 2016). In case of external 
aggression of host cells, immune cells can recognize foreign pathogens and generate a 
response able to fight them. Mucus and enzymes are the first barrier to prevent the 
foreign aggressors to establish an infection. If they penetrate, there is a recruitment of 
immune cells to the site of infection that phagocyte infectious agents, produce anti-
microbial peptides and secrete cytokines able to initiate the process responsible for their 
elimination (Mackay et al. 2000). 
Beutler states that all “true” immune system must be able to discriminate between self 
and non-self, tolerating self (sparing host tissues from damage) and attacking non-self 
(Beutler 2004). Accordingly to this point of view, Charles Janeway and Ruslan Medzhitov 
believe that the major decision to respond, or not, to a particular ligand or antigen is 
decided by the genome encoded innate immune system receptors present in the surface 
of immune cells. When the immune cells encounter pathogen-associated molecular 
patterns (PAMPs), such as flagellin, lipopolysaccharides (LPS) and/or nucleic acids like 
viral dsDNA/RNA and unmethylated CpG dinucleotides in bacterial DNA, they recognize 
them as non-self and create an immune response against the pathogens that have them. 
However, the immune system responds as well to damage-associated molecular patterns 
(DAMPs), such as nuclear or cytosolic proteins, heat shock proteins (Hsps), adenosine 
triphosphate molecule (ATP) outside cells and host cell’s DNA and RNA (Matzinger 2002). 
Therefore and in contrast to Janeway and Medzhitov, Polly Matzinger proposed the 
Danger model, which suggests that the immune system is more concerned with the 
damage done in host cells than with the foreignness of a certain pathogen. The immune 
system is then called into action by alarm signals released by injured tissues, rather than 
by the recognition of non-self pathogens or molecules (Matzinger 2002). 
 
There are two distinct types of responses: Innate and adaptive immunity responses.  
 
Innate immunity encompasses host defences at the time a danger signal is released. 
Its role is to limit spreading of an infection and constrain the aggression of infectious 
pathogens. It has no specificity for any type of infectious pathogen or transformed cells 
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and occurs as many times the alarm signal appears with similar amplitude and speed 
(Nicholson 2016) (Matzinger 2002).  
 
Myeloid cells (MC); macrophages, dendritic cells (DCs), granulocytes (neutrophils, 
eosinophils and basophils) and mast cells; natural killer (NK) cells, γδ T cells and NKT 
cells are immune cells responsible for innate immune responses. Macrophages, DCs and 
neutrophils are able to phagocyte pathogens and produce inflammatory cytokines. 
Macrophages also promote wound healing and regulate adaptive immunity by activating T 
cells through the production of cytokines or functioning as antigen presenting cells 
(APCs). DCs are specialized APCs, effectively stimulating immune responses and 
promoting effector T cell differentiation (Janeway & Medzhitov 2002). Basophils, 
eosinophils and mast cells produce inflammatory mediators. NK cells are able to destroy 
infected and transformed cells, in particular those which do not display the major 
histocompatibility complex class I (MHCI) molecule in their surface. They induce apoptosis 
in transformed cells via production of perforin and granzyme (Bodduluru et al. 2015). 
Other pathway responsible for the induction of apoptosis is the Fas/Fas ligand pathway. 
The engagement of Fas by Fas ligand results in apoptosis, mediated by caspase 
activation (Trapani & Smyth 2002) (Waring & Müllbacher 1999). NKG2D is an activation 
receptor expressed on the cell surface of NK cells, NKT cells, γδ T cells, some cytotoxic 
CD8+ T cells and a small subset of CD4+ T cells associated with detection and 
elimination of transformed cells. NKG2D can recognize stress-induced molecules, such as 
retinoic acid early transcript 1 (Rae-1) and dominant minor antigen 60 (H60) displayed on 
the surface of transformed and infected cells, promoting their destruction (Smyth et al. 
2005). 
 
Adaptive immunity, as opposed to innate immunity, creates an immunological 
memory against specific pathogens or antigens. After an encounter with a given 
pathogen, it mounts faster and more robust responses, capable of protecting the host 
from secondary exposures and being the main immune system characteristic for 
vaccination (Beutler 2004) (Janeway & Medzhitov 2002). Adaptive immunity includes 
responses mediated by T cells and B cells against a specific target, following the 
exposure to a given antigen displayed by APCs. T cells are divided in αβ T cells and γδ T 
cells, according to the chains that constitute their T cell receptor (TCR). Naïve αβ T cells 
circulate in the blood and are activated in secondary lymphoid organs by APCs that 
process antigens and display them conjugated with MHCI and II molecules in their 
surface. T cells perform helper (CD4+ T cells) or cytotoxic (CD8+ T cells) functions. CD4+ 
T cells secrete cytokines and CD8+ T cells produce cytolytic enzymes. CD4+ T cells play 
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a central role in the immune responses, and  are required for CD8+ T cell responses and 
B cell responses. Through the production of cytokines and chemokines, they can 
orchestrate immune responses by aiding B cells create antibodies, inducing macrophages 
to develop enhanced inflammatory and microbicidal activity, recruiting neutrophils to sites 
of infection and inflammation and inducing anti-tumour cytotoxic T lymphocytes (CTL) 
responses (Zhu & Paul 2008) (Melief 2013). CD4+ T cells can differentiate into T helper 
cells type 1 and type 2. T helper type 1 cells (TH1) produce interferon γ (IFN-γ), 
interleukin 2 (IL-2) and tumour necrosis factor (TNF), and are able to activate 
macrophages and induce cell-mediated cytotoxicity. T helper type 2 cells (TH2) CD4+ T 
cells produce large amount of IL-4, IL-10, and IL-13, and induce strong antibody 
responses, but inhibit several inflammatory functions of phagocytic cells (Romagnani 
2000). A population of CD4+ regulatory T cells (Treg) are responsible for immunological 
self-tolerance by actively suppressing self-reactive lymphocytes. They express Foxp3, a 
key transcription factor for their development, and are identified as CD4+Foxp3+ T cells 
(Hori et al. 2003). The CD8+ T cells can become activated and classified as CTLs that 
induce cell-mediated cytotoxicity through perforin/granzyme or Fas/FasL apoptosis 
pathways. B cells secrete antigen-specific antibodies (immunoglobulins) that bind to 
viruses, microbial toxins and surface antigens, eliminating microorganisms and tumour 
cells. 
 
Some lymphocytes of the adaptive immunity also display features of the innate 
immunity, developing a very rapid and pre-committed response to a given stimuli. These 
include γδ T cells and NK T cells, which represent a bridge between the two arms of the 
immune system. γδ T cells mainly populate epithelial tissues and respond to stress 
signals, recognizing stress-induced self-antigens (Hayday 2000). Similarly, NKT cells are 
a subset of T cell that have similar features with both, conventional T cells and NK cells 
(Godfrey et al. 2004). Thus, both γδ and NK T cells combine expression of a TCR, can 
recognize antigens without restriction to MHCI or II associated peptide ligands and 
express NK cell functional cytotoxic receptors on their cell surface. Thus, like NK cells, γδ 
T cells have cytolytic functions capable of eradicating infected and transformed cells 
(Groh et al. 1998) (Hayday 2009). 
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2. Myeloid cells lineages and functions in immunity 
 
2.1. Myeloid cells lineages and functions 
The immune cells present in the blood arise from pluripotent haematopoietic stem 
cells (HSCs) in the bone marrow. The HSCs can divide in two types of multipotent stem 
cells: a common lymphoid progenitor, which gives rise to NK cells and T and B 
lymphocytes, and a common myeloid progenitor, that gives rise to leukocytes, 
erythrocytes and platelets (Janeway et al. 2005). MC are composed of monocytes, 
macrophages, granulocytes (neutrophils, eosinophils and basophils), dendritic cells and 
mast cells. They are extremely short-lived (survive less than three days before undergoing 
apoptosis) when compared to lymphoid cells and perform important functions in the innate 
immune response. 
Markers 
CD11b is an integrin associated with various adhesive interactions of MC. It is 
expressed on monocytes, macrophages, granulocytes and in some DCs and B cells, thus 
being a marker for myeloid cells (McNally & Anderson 2002) (Cassado et al. 2015). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Myeloid cell lineages differentiation under normal physiological conditions. Adapted 
from Gabrilovich, Ostrand-Rosenberg and Bronte 2012 
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2.2. Monocyte differentiation and functions 
Monocytes can be generated within the fetal liver and in the bone marrow in adult life. 
They are derived from macrophage and DC precursors (MDPs) and common monocyte 
progenitors (cMoPs), which arise from granulocyte/macrophage progenitor (GMP) in the 
bone marrow (Ginhoux & Jung 2014). Adult monocytes are present in the bone marrow, 
blood and spleen and their development and survival is dependent on colony-stimulating 
factor 1 (also referred as M‑CSF). Mice deficient in M‑CSF or its receptor, CSF1R (also 
known as CD115 or M‑CSFR), exhibit severe monocytopenia (Dai et al. 2002). 
Monocytes patrol extravascular tissues and remain immature, being able to undergo a 
differentiation program. They acquire specific functions through the response to signals 
derived from damaged tissues, and lymphocytes. During infection and inflammation, 
monocytes migrate to affected tissues where they produce cytokines and differentiate into 
macrophages or DCs. Their migration and differentiation is determined by the 
inflammatory milieu where they carry out specific effector functions (Geissmann et al. 
2010). During inflammation, they produce tumour necrosis factor α (TNF-α), IL-1β, 
inducible nitric oxide synthase (iNOS) and upregulate MHCII molecules (Biswas & 
Mantovani 2010) (Yang et al. 2014). Auffray and colleagues denote two types of 
monocytes: Inflammatory monocytes, recruited into inflamed tissues and lymph nodes, 
and patrolling monocytes, found in both resting and inflamed tissues (Auffray et al. 
2007). Inflammatory monocytes express the cell surface protein Ly6C, L-selectin and 
the chemokine receptor CCR2 and can differentiate into inflammatory macrophages and 
DCs. Some studies suggest that they can also differentiate, mostly in the circulation, into 
Ly6Clow monocytes (Yona et al. 2013). By contrast patrolling monocytes express high 
levels of the chemokine receptor CX3CR1, LFA-1 integrin (and lack the expression of 
Ly6C, CCR2 and L-selectin). The different adhesion molecules and chemokine receptors 
expression, suggest different types of tissue trafficking. Intravital microscopy, revealed 
that monocytes within most blood vessels exhibited “constitutive crawling type motility” 
and, in contrast, “rolling” monocytes were observed only transiently in the mesenteric 
veins and not in arteries, giving rise to the two monocyte subsets (Auffray et al. 2007).  
 
2.3. Macrophage ontogeny 
Studies based on the inactivation of the transcription factor c-Myb, critical for HSCs 
development, showed that adult tissue-resident macrophages were derived during 
embryogenesis from yolk sac progenitors and not from blood monocytes (Schulz et al. 
2012). Thus, macrophage populations can result from primitive haematopoietic 
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progenitors generated in the yolk sac and fetal liver and from bone-marrow monocytes 
(Lahmar et al. 2016) (Ginhoux & Jung 2014). Yolk sac-derived macrophages are the 
first to colonize the tissues but their population is later diluted with the arrival of fetal liver-
derived monocytes. Brain microglia arise predominantly from yolk sac-derived 
macrophages while lung alveolar macrophages, liver Kupffer cells, epidermal Langerhans 
cells and heart macrophage populations are mainly resultant from fetal liver-derived 
monocytes. All tissues also contain adult monocyte-derived macrophages generated 
from the bone marrow (Ginhoux et al. 2010) (Ginhoux & Jung 2014). Despite differences 
in ontogeny, all tissue-resident macrophages are important for tissue integrity and 
manifest a suppressive function in steady-state conditions. For example, yolk sac–derived 
microglia and fetal liver–derived alveolar macrophages exert immunosuppressive 
functions by selectively inhibiting T cell activation and proliferation (Ginhoux et al. 2015). 
In contrast, during inflammation, blood monocytes are recruited and give rise to 
monocyte-derived macrophages and DCs that undergo programming of their functional 
properties in response to signals derived from microbes, damaged tissues, and activated 
lymphocytes (Biswas & Mantovani 2010). Altogether, these evidences suggest that it is 
the tissue that determine macrophage functions and not their origin (Guilliams & Scott 
2017).  
2.4. Macrophage functions during immune responses 
Macrophages can be activated by a variety of stimuli, initiating and actively 
participating in the polarisation of immune responses (Duque & Descoteaux 2014). After 
exposed to inflammatory stimuli, macrophages secrete cytokines, such as TNF-α, IL-1, IL-
6, IL-8, and IL-12, chemokines, leukotrienes, prostaglandins, and complement proteins. 
These molecules induce increased vascular permeability and recruitment of inflammatory 
cells, allowing for the extravasation of monocytes and neutrophils and infiltration of 
lymphocytes to the site of inflammation (Duque & Descoteaux 2014). TNF-α and IL-1β are 
two of the most prominent pro-inflammatory cytokines expressed by macrophages. TNF-α 
is a glycoprotein that was initially described for its ability to induce necrosis in tumours and 
is responsible for the destruction of transformed cells by macrophages (Carswell et al. 
1975). IL-1β is a pro-inflammatory cytokine secreted by macrophages that help in the 
elimination of infectious agents. It is capable of inducing strong and durable CD4+ T cell 
responses and enhance their expansion and differentiation (Ben-Sasson et al. 2009). 
Upon toll-like receptors (TLR) activation, IL-1β is produced via the inflammasome, a 
multimolecular complex composed of NOD-like protein (NLR), apoptosis-associated 
speck-like protein comprehending a caspase recruitment domain (ASC) and caspase-1. 
Caspase-1 is activated through interaction with ASC and is responsible for the cleavage of 
8 
 
pro-IL-1β into its active form (Tschopp et al. 2003) (Guo et al. 2016). Macrophages also 
directly promote CD4+ and CD8+ T cell proliferation and maturation through their APC 
functions (Moser 2001) (Pozzi et al. 2005). Adoptive transfer of macrophages  
demonstrated that they could prime naive CD8+ T cells to proliferate and mature into both 
effector and memory cells (Pozzi et al. 2005). 
Markers 
Almost all mouse mature macrophages express a unique surface antigen - a 
epidermal growth factor glycoprotein - recognized by the F4/80 monoclonal antibody 
(mAb). F4/80 mAb bind to lung, spleen, thymus and peritoneal macrophages, blood 
monocytes and bone marrow derived macrophage precursors (Morris et al. 1991) (Austyn 
& Gordon 1981). F4/80 mAb also recognise eosinophils in several organs (Cassado et al. 
2015) but they are distinguished from macrophages due to their expression of siglecF, a 
lectin receptor (Zimmermann et al. 2008). 
 
2.5. Granulocyte origin and functions during immune response. 
Granulocytes (neutrophils, eosinophils and basophils) differentiate from GMPs 
and are characterized by the presence of cytoplasmic granules and a particular nuclear 
morphology.  
Neutrophils are the most abundant of the granulocytes and can be commonly 
referred as polymorphonuclear leukocytes. They are specialized in phagocytosis, having a 
complex machinery to engulf and destroy pathogens (Beutler 2004; Gabrilovich et al. 
2012). They are short-lived cells, surviving in the circulation for only about eight to ten 
hours before undergoing apoptosis. Neutrophils can destroy pathogens through 
phagocytosis (uptake of opsonized and/or engulfed pathogens), production of reactive 
oxygen species and release of cationic peptides (degranulation), and formation of 
neutrophil extracellular traps (NETs) (Mayadas et al. 2014). They can also produce 
cytokines and chemokines, such as B cell–activating factor (BAFF), IL-23 and CCL3, able 
to regulate other immune cell migration and functions (Mayadas et al. 2014). Neutrophils 
were also reported as APCs, expressing low levels of MHCII molecules and costimulatory 
molecules after stimulation with IFN-γ, granulocyte macrophage colony-stimulatory factor 
(GM-CSF) and IL-3 (Abdallah et al. 2011).  
Eosinophils mostly accumulate during parasitic infections and are weakly 
phagocytic. Upon activation, they kill parasites mainly by releasing cationic proteins and 
reactive oxygen metabolites into the extracellular fluid (Mackay et al. 2000). They also 
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promote inflammation by secreting leukotrienes, prostaglandins, and various cytokines. 
Eosinophils have been also reported to mediate cytotoxicity activity against some types of 
tumours and support tumour rejection when CD8+ T cells where present in the 
microenvironment (Carretero et al. 2015) (Gatault et al. 2015).  
Basophils and mast cells have similar functions. Basophils are present mainly in the 
blood whereas mast cells are predominant in the skin, airways and intestine. Both types of 
cells possess high-affinity receptors for IgE (FcεR) and thereby become coated with IgE 
antibodies. In atopic allergies such as eczema, hay fever, and asthma, allergens bind to 
the IgE that cross-links the FcεR and triggers the cell to secrete inflammatory mediators 
such as histamine, prostaglandins, and leukotrienes producing a strong allergic and 
inflammatory response (Mackay et al. 2000). 
Markers 
Ly6G is a surface protein expressed on neutrophils, and transiently during 
developmental stages of monocytes. In 2004 it was confirmed the absence of cross-
reactivity between murine Ly6C and Ly6G mAbs, allowing for a better discrimination of 
myeloid cells (Nagendra & Schlueter 2004). As described before, eosinophils can be 
differentiated from the other populations through their expression of siglecF (Zimmermann 
et al. 2008). 
  
2.6. Dendritic cells ontogeny and functions during immune response. 
DCs are terminally differentiated myeloid cells that specialize in antigen processing 
and presentation to T cells (Gabrilovich et al. 2012). DCs differentiate in the bone marrow 
from MDPs that derive in common DC precursors (CDPs). During infection or 
inflammation, they can also differentiate from blood monocytes (Geissmann et al. 2010).  
DCs reside in tissues as immature cells that actively uptake tissue antigens and 
phagocyte pathogens, but are poor antigen presenters. They have low expression of MHC 
molecules and lack B7 co-stimulatory molecules. When functionally activated, DCs 
maturate and migrate to the lymph node where they synthesize MHC molecules and 
express B7 molecules, in order to effectively stimulate naïve antigen-specific T cells. They 
start to express a large number of adhesion molecules, which stabilizes the interaction 
between T cell TCR and peptides presented through MHC molecules. DCs also secrete 
cytokines like IL-12 and IL-18 to promote TH1 and cytotoxic CD8+ T cell responses 
(Greenwald et al. 2005) (Vanneman & Dranoff 2014) (Merad et al. 2013). CD40 signalling, 
was also reported to induce the upregulation of MHCII, co-stimulatory and adhesion 
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molecules in DCs, which make them more effective APCs (Ma & Clark 2010). CD40 
ligand induces the production of massive amounts of IL-12 by DCs, resulting in enhanced 
T cell stimulatory capacity (Celia et al. 1996). 
Markers 
CD11c expression is a marker of DCs but it is not specific (being expressed also by 
macrophages, monocytes, NK cells, and activated T cells). However, by excluding 
macrophages with F4/80 mAb (DCs do not express F4/80) one should accurately 
visualize DCs using flow cytometry (Merad et al. 2013). 
 
3. Macrophage polarization during inflammation 
3.1. Macrophage polarization (M1 vs M2). 
There are two distinct polarized macrophage states: the classically-activated 
macrophage (M1) and the alternatively-activated macrophage (M2) (Biswas & 
Mantovani 2010). M1, typically activated by IFN-γ and LPS, exhibit potent microbicide 
properties and promote strong IL-12-mediated TH1 responses. In contrast, M2, induced 
by IL-4 and IL-13, support TH2 associated effector functions and may play a role in the 
resolution of inflammation (Geissmann et al. 2010). Factors such as IL-10, 
glucocorticoids, and transforming growth factor β (TGF-β) induce phenotypes that partially 
overlap with the M2, contributing to the cytokines associated with M2 features 
(Ghassabeh et al. 2006).Thus, monocytes are polarized by the microenvironment or 
inflammatory milieu to mount specific functional programs accordingly to the cytokines 
that are available (Mantovani et al. 2002). 
Classicaly-activated M1 macrophages are effector cells characterized by killing 
pathogens, eliminating tumour cells and as efficient APCs. M1 produce large amounts of 
pro-inflammatory cytokines, such as IL-12, IL-23 and TNF-α, iNOS and have higher 
expression of MHCII and costimulatory molecules (Mantovani et al. 2002). They are 
polarized during TH1 responses and their ability to produce IL-12, CXCL9 and CXCL10, 
drive the recruitment of TH1 cells, thereby amplifying the loop for type 1 responses 
(Biswas & Mantovani 2010). M1 macrophages metabolize arginine via nitric oxide 
synthase (NOS) to nitric oxide (NO) and citrulline. Thus, arginine metabolism is 
characterized by high levels of inducible iNOS in M1 macrophages (Rath et al. 2014).  
Alternatively-activated M2 macrophages are characterized by high phagocytic 
activity, high expression of scavenging receptors, promoting angiogenesis, tissue 
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remodelling and repair and are associated with tumour progression (Mantovani et al. 
2002) (Biswas & Mantovani 2010). They express large amounts of IL-10 and low 
quantities of IL-12. They express a selective set of chemokines, including CCL17, CCL22 
and CCL24, which results in the recruitment of TH2 cells, Treg cells, eosinophils and 
basophils, amplifying polarized TH2 responses (Biswas & Mantovani 2010). M2 
macrophages metabolize arginine, via arginase, to ornithine and urea. Thus, M2 are 
characterized by high production of arginase (Rath et al. 2014). 
 
 
 
 
Figure 2: Characteristics of M1, M2 and M2 like polarized macrophages induced by IFN-γ and 
LPS (in green); IL-10 (in red); IL-4 and IL-13 (in yellow); and IL-4, IL-13, IL-10 (in blue). Adapted 
from Mantovani 2012 
 
4. Immune cells control tumour development and growth 
The concept that the immune system is very important in the destruction of cancer 
cells and that it can recognize and control tumour growth is not new. In 1893, William 
Coley used live bacteria as an immune stimulant to treat cancer. After stimulation, the 
immune system could recognize tumour cells and control tumour growth (Yang 2015). 
Lewis Thomas (1959) and Frank Burnet (1970) were the first to propose the concept of 
tumour immune surveillance. The tumour immune surveillance hypothesis defends that 
the immune system has the ability to identify and destroy nascent tumours, operating as a 
primary defence against cancer (Swann & Smyth 2007). Most recently was demonstrated 
that the immune system not only can protect the host against tumour development but 
also, by selecting for tumours of lower immunogenicity, has the capacity to promote 
tumour growth of resistant malignant cells (Dunn et al. 2004). This dual effect of the 
immune system on developing tumours prompted Gavin Dunn, Lloyd Old and Robert 
Schreiber to redefine the cancer immunosurveillance hypothesis into one they termed 
cancer immunoediting.  
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Figure 3: The three phases of cancer immunoediting: elimination, equilibrium and escape. 
Adapted from Swann and Smyth 2007 
 
They envisaged that the cancer immunoediting process is comprised of three phases: 
elimination, equilibrium, and escape (Dunn et al. 2004). In the elimination phase, the 
immune system detects and eliminates tumour cells that have developed as a result of 
failed tumour suppressor gene activation or damage repair mechanisms. This phase is 
complete when all tumour cells are cleared, or incomplete, when only a portion of tumour 
cells is eliminated. If not all cancer cells are destroyed, it is predicted that they either 
remain dormant or continue to accumulate DNA mutations and/or changes in gene 
expression. The tumour cells can, for example, modify the expression of surface antigens 
evading immune recognition and, consequently, destruction. As this process continues, 
the immune system exerts a selective pressure by eliminating susceptible tumour clones, 
which is sufficient to control tumour progression. However, the process can result in the 
selection of tumour cell clones that are able to resist, avoid, or suppress the anti-tumour 
immune response, leading to the escape phase. During the escape phase the immune 
system is no longer able to contain the progressive tumour growth. 
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Various animal experiments were performed in order to test the effect of the immune 
system in controlling tumour formation (Corthay 2014). One of the first approaches was to 
eliminate specific and essential components of the mouse immune system and observe 
them for the development of tumours (Swann & Smyth 2007). In 2001, Shankaran and 
colleagues describe that the immune response functions as an effective tumour-
suppressor system, showing that primary immunodeficiency in mice is associated with 
increased cancer risk. In their experiment, recombination activating gene 2 deficient mice 
(Rag2–/–), which lack both B and T cells, developed chemically methylcholanthrene 
(MCA) induced tumours earlier than wild-type (WT) mice and with greater frequency (60% 
vs 20%) (Shankaran et al. 2001). Rag2–/– mice had higher incidence of spontaneous 
adenocarcinoma of the intestine and lung and intestinal adenomas when compared to WT 
mice. When Rag2–/– mice were also deficient for STAT1, an important transcription factor 
mediator of type I and type II interferon (IFN) signalling, tumour incidence was increased 
and the spectrum of tumours was augmented with breast adenocarcinomas and colon 
adenocarcinomas (Shankaran et al. 2001). Mice deficient for NKG2D also had a greater 
incidence of MCA-induced fibrosarcomas than control mice (Smyth et al. 2005). This is 
due to the NKG2D ligands upregulation on tumour cells, such as Rae1, not being 
recognized by primed cytotoxic T cells and NK cells, which fail to eliminate cancer cells 
(Diefenbach et al. 2001). These results show that distinct cell surface ligands, expressed 
often by tumour cells, but not by normal cells, can be associated with malignant 
transformation and allowing immune cells to recognize and kill tumour cells. It was also 
described that mice lacking γδ T cells were highly susceptible in developing cutaneous 
carcinomas (Girardi et al. 2001). Upon exposure to carcinogens, skin transformed cells 
express ligands for NKG2D like Rae-1 and H60 allowing for NKG2D+ γδ T to recognize 
these ligands in the surface of skin carcinoma cells, killing them (Girardi et al. 2001). 
 
A number of clinical observations also provided evidence supporting the importance 
of innate and adaptive immune system in allowing or controlling tumour development. 
Clinical trials showed that patients with primary immunodeficiency had higher risk of 
developing lymphoproliferative disorders like non-Hodgkin’s lymphomas (60%), Hodgkin’s 
disease (23%) and leukaemia (6%) (Salavoura et al. 2008). Organ transplant patients 
subjected to immunosuppressive treatments had three times the number of neoplasms 
when compared with age-matched controls (Penn 1988). Tumours infiltrated with T 
cells have been associated with improved prognoses (Haanen et al. 2006) (Zhang et al. 
2003) (Galon et al. 2006). An association between patient prognosis and tumour 
infiltrating lymphocytes (TILs) was first observed in patients with melanoma. The presence 
of tumour associated antigen (TAA) specific TILs improved survival in advanced-stage 
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resected melanoma patients (Haanen et al. 2006). Moreover, in ovarian cancer the 
presence of TILs correlates with improved progression-free survival and overall survival 
and is associated with increased expression of IFN-γ and IL-2 (Zhang et al. 2003). In 
colon-rectal cancer the presence of TH1, cytotoxic and memory T cells was related with 
low incidence of tumour recurrence (Galon et al. 2006). Treg cells demonstrate an inverse 
correlation between presence of tumour infiltrating Treg cells and patient survival by 
suppressing endogenous TAA specific TILs cell immunity (Curiel et al. 2004). 
 
 
5. Cancer Immunotherapy 
The development of novel immunotherapeutic approaches, which aim at stimulating 
cytotoxic T cells, have revolutionized treatments against cancers. These treatments 
include infusion of re-activated tumour-infiltrating T lymphocytes, immune checkpoint 
inhibitors and vaccination strategies (Vanneman & Dranoff 2014). 
 
5.1. Adoptive T cell transfer therapy 
Adoptive transfer of TILs was shown to induce long-lasting responses and complete 
regression of metastatic melanoma tumours (Rosenberg et al. 2011). In combination with 
IL-2, the response rate was increased in approximately 15%, with 5% durable complete 
responses. A clinical trial from Rosenberg and colleagues resulted in 56% clinical 
responses and 22% complete responses of treated patients. However and despite TILs 
can be harvested from a variety of cancers, with the exception of melanoma TILs adoptive 
transfer rarely demonstrate tumour elimination (Hinrichs & Rosenberg 2014). To 
overcome this problem various types of genetically engineered T cells have been created. 
Adoptive transfer of autologous T cells that are gene transduced to express antigen-
specific receptors represents a promising therapy to provide tumour-specific immunity to 
cancer patients (Hinrichs & Rosenberg 2014). The most promising results from 
engineered T cells come from the chimeric antigen receptor CAR T cells. CARs are 
constructed of antibody single-chain variable fragments joined with TCR and costimulatory 
molecule domains, which confers T cells the ability to bind more efficiently to cell surface 
antigens. As an example, CAR T cells have been created with good results to target B-cell 
malignancies using anti-CD19 single Ab chain (Kochenderfer et al. 2010). Novel 
strategies to target other cancer types are being developed. 
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5.2. Immune checkpoint inhibitors 
A promising novel strategy to treat cancer consists in potentiating the naturally 
occurring immune response of the patient through blockade of immune checkpoint 
molecules. Once activated, T cells upregulate on their cell surface two co-inhibitory 
molecules: cytotoxic T lymphocyte associated antigen 4 (CTLA-4) and programed death 1 
(PD-1). CTLA-4 binding counters early T-cell activation, leading to a decrease of IL-2 
production and inhibition of cell cycle progression. Similarly, PD-1 has been described as 
a negative regulator of immunity that limits the production of IFN-γ and T cell proliferation, 
and increasing T-cell apoptosis. It is hypothesised that CTLA-4 acts early in tolerance 
induction while PD-1 acts late in long-term tolerance maintenance (Fife & Bluestone 
2008). CTLA-4 inhibits T-cell activation in lymphoid organs, while PD-1 contributes to T-
cell exhaustion in peripheral tissues indicating that CTLA-4 and PD-1 play complementary 
roles in regulating adaptive immunity (Fife & Bluestone 2008). For the purpose of cancer 
immunotherapy, monoclonal antibodies have been generated to potentiate the ongoing 
anti-tumour immune response of the patient, through blockade of CTLA-4, PD-1, or PD-1 
ligand (PD-L1) (Corthay 2014) (Dunn et al. 2004) (Swann & Smyth 2007).  
Ipilimumab is an antibody against CTLA-4 for treatment of patients with metastatic 
melanoma. Treated patients showed a prolonged overall survival compared to non-treated 
patients (Hodi et al. 2010). Nivolumab is an antibody against PD-1 that has been shown to 
produce durable tumour regression responses in clinical trials (Topalian 2012). On the 
basis of their distinct immunologic mechanisms of action and supportive preclinical data, 
some clinical trials were made to combine nivolumab with ipilimumab. In patients with 
advanced melanoma, combined therapy showed rapid and deeper clinical tumour 
responses in comparison with the previous experiences with either agent alone (Wolchok 
et al. 2013). 
 
5.3. Vaccination therapies 
Therapeutic vaccines are used to treat cancer patients, promoting the recognition and 
elimination of tumour cells by the host immune system. The anticancer vaccines have 
several subtypes depending on their constitution and action mechanisms: dendritic cells, 
carbohydrates, genetic (DNA or RNA), whole cells, and peptides/proteins all belong to 
cancer vaccines (Yang 2015). Many vaccines have promising results in clinical trials and 
some are already in use in the clinic. From the most promising vaccines we can 
discriminate:  Sipuleucel-T™, already approved by the FDA in 2010, an autologous 
dendritic cell vaccine destined for mCRPC patients (Cheever & Higano 2011) (Kantoff et 
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al. 2010), Oncovax™, an autologous vaccine derived directly from the patients tumour in 
combination with Bacillus Calmette-Guérin (BCG) as adjuvant (Huang et al. 2015); 
NeuVax™, a peptide vaccine used for the treatment of HER2+ breast and ovarian cancer 
(Chablani 2013); ValloVax™, an anti-angiogenic vaccine derived from placental 
endothelial cells (Wagner et al. 2015); and PROSTVAC™, a genetic vaccine for the 
treatment of metastatic castration-resistant prostate cancer (mCRPC), that combines 
prostate specific antigen (PSA) and molecules able to stimulate T cell recognition and 
killing of PSA expressing cells (Mandl et al. 2014). 
Despite the clear efficacy of immunotherapy, regrettably only a small proportion of 
patients benefit from complete response and long-term tumour remission. This is partially 
explained because tumour cells have the ability to avoid recognition and elimination by the 
immune system, which represents a major drawback for the actual immunotherapy 
strategies (Yang 2015). 
 
6. Tumour cells manipulate immune cells 
In 2000, Hanahan and Weinberg proposed six hallmarks of cancer, tumour cells 
unique and complementary capabilities, required for its growth and metastatic 
dissemination:  sustaining proliferative signalling, evading growth suppressors, resisting 
cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion 
and metastasis. In the 2011 revised version of the hallmarks of cancer, Hanahan and 
Weinberg added two more emerging hallmarks: reprogramming of energy metabolism and 
evading immune destruction. The addition of the last hallmark was critical due to the 
arguments (discussed above) showing major contributions of immune cells to tumour 
destruction or development (Hanahan & Weinberg 2011).  
 
6.1. Tumour microenvironment 
Tumours are not isolated masses of proliferating cancer cells but composed of 
distinct haematopoietic and stromal cell types that participate in heterogeneous 
interactions with one another, contributing to  tumour promotion (Galdiero et al. 2013) 
(Elpek et al. 2014). Tumours depend on the availability of blood vessels and inflammatory 
infiltrative cells. Angiogenesis is essential for tumour growth, allowing the tumour access 
to nutrients and growth factors present in the blood. Cancer cells produce cytokines and 
chemokines that are mitogenic and/or chemoattractants for granulocytes, 
monocytes/macrophages, fibroblasts and endothelial cells. The infiltration of these cells 
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and the factors they produce potentiate tumour growth, stimulate angiogenesis, induce 
fibroblast migration and maturation, and enable metastatic spread via venous or lymphatic 
vessels (Coussens & Zena 2002).  
 
6.2. Tumour manipulation of immune cells 
Tumour infiltrating immune cells can be anti-tumour, able to eliminate cancer cells 
mostly in the early stage of tumour formation, or pro-tumour, allowing and favouring 
tumour growth and progression (Mantovani 2014). The tumour microenvironment is able 
to damper these early pro-inflammatory features and more importantly convert them into 
potent immunosuppressive cells (Galdiero et al. 2013) (Fridlender et al. 2012) (Gabrilovich 
et al. 2012).  There is growing evidence that the tumour-mediated upregulation of 
immunosuppressive cytokines like TGF-β and IL-10, promote aberrant differentiation of 
myeloid lineage cells (Fridlender et al. 2009). In this case, myeloid cell progenitors in the 
bone marrow give rise to immature myeloid cells with immunosuppressive potential, often 
referred to as myeloid-derived suppressor cells (MDSC) (Elpek et al. 2014).  
The recent realization that infiltrative myeloid cells display pro-tumour features is 
demonstrated by an increase in MDSC in the blood of cancer patients associated with bad 
prognosis in various types of tumours, such as pancreatic (Xu et al. 2016) bladder 
(Eruslanov et al. 2012), oesophageal and gastric cancers (Gabitass et al. 2011) and 
colorectal carcinoma (Zhang et al. 2013). Moreover, in a spontaneous mouse model, the 
depletion of pro-tumour myeloid cells (PTMc) inhibits tumour growth and reduces the level 
of immunosuppression in the tumour microenvironment, allowing for increased activity of 
CTLs (Pekarek et al. 1995). These immature immunosuppressive myeloid cells are 
divided into monocytic MDSC (Mo-MDSC - CD11b+ GR1mid Ly6Chi Ly6G–) and 
granulocytic MDSC (G-MDSC - CD11b+ GR1hi Ly6Clow Ly6G+) (Youn et al. 2008) 
(Movahedi et al. 2008).  
 
6.3. MDSC infiltrate tumour and differentiate into tumour-associated 
macrophages and neutrophils  
Kusmartsev and colleagues demonstrated that GR1+ immature myeloid cells start to 
accumulate in tumour tissues 16 hours after being adoptively transferred, being potential 
precursors of tumour-associated myeloid cells. The findings give strength to the 
hypothesis that MDSC infiltrate tumours and differentiate into mature tumour-associated 
macrophages (TAM) or tumour-associated neutrophils (TAN) (Kusmartsev et al. 
2005). However, Fridlender and co-workers describe TAN not as ‘‘tissue-based G-
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MDSC’’, but as a distinct subset of neutrophils, differing from naive steady-state 
neutrophils and G-MDSC by the dissimilarities of their transcriptomic profile (Fridlender et 
al. 2012). It is still not clear whether TAM and TAN derive from MDSC that infiltrate 
tumours or whether they are blood-derived monocytes and neutrophils converted into 
TAM and TAN, respectively by high local concentrations of immunosuppressive cytokines, 
such as TGF-β and IL-10 (Fridlender et al. 2009). 
 
 
 
Figure 4: MDSC mechanisms responsible for the inhibition of T cell activation and proliferation. 
Adapted from Gabrilovich, Ostrand-Rosenberg and Bronte 2012 
 
6.4. Tumour-associated macrophages 
Similar to the macrophage polarization into a M1 or M2 phenotype during 
infection/inflammation, TAM can also have different functions, inhibiting or promoting 
tumour growth (Biswas & Mantovani 2010) (Mantovani 2014). Macrophages isolated from 
mouse and human tumours share M2 macrophages properties (Biswas et al. 2006). In 
vivo analysis of TAM through immunohistochemistry and confocal microscopy show their 
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high expression of IL-10, scavenger receptors, angiogenic factors and phagocytosis-
related molecules and low expression of IL-12, exhibiting similar functions between M2 
macrophages and TAM. Unexpectedly, TAM upregulated IFN inducible chemokines, such 
as CXCL9, CXCL10 and CXCL16, associated with TH1 responses (Biswas et al. 2006).  
Despite some authors describing TAM as having an M2-like phenotype, because of 
their mixed anti or pro-tumour functions they will be referred as anti-tumour 
macrophages (ATMa) or as pro-tumour macrophages (PTMa). PTMa perform many 
functions, including extracellular matrix remodelling, promotion of tumour cell invasion and 
metastasis, angiogenesis and immune suppression. They express high amounts of TGF-
β, arginase-1, IDO, and IL-10, known for being immunosuppressive molecules (Mantovani 
2014). Additionally, PTMa have been shown to express PD-L1 (B7-H1) in some types of 
cancer, associated with immunosuppressive functions (Kuang et al. 2009). In a report 
from Kuang and colleagues, PD-L1+ macrophages from stroma of patients with 
hepatocellular carcinoma, effectively induced dysfunctional T cells with low cytotoxicity 
and with impaired capacities for proliferation and production of IL-2 and IFN-γ (Kuang et 
al. 2009). 
 
6.5. Tumour-associated neutrophils 
TAN have been proposed as promotors of malignant transformation, tumour 
progression and angiogenesis through the production of granule proteins, cytokines and 
angiogenic factors (Mantovani 2014). However, they have been also associated with anti-
tumour functions upon stimulation with type I IFN (Jablonska et al. 2010) or after TGF-β 
blockade (Fridlender et al. 2009) (Zhang et al. 2016). Therefore, TANs can have pro-
tumour or anti-tumour functions, thus being referred henceforth as anti-tumour 
neutrophils (ATNe) or as pro-tumour neutrophils (PTNe). PTNe from human lung 
cancers secreted CCL17, a Treg cell chemoattractant chemokine that promotes the 
inhibition of cytotoxic T cell activity and enables tumour immune evasion (Mishalian et al. 
2014). Depletion of PTNe was shown to inhibit tumour growth and reduce the level of 
immunosuppression in the tumour microenvironment, allowing for increased activity of 
CTLs (Pekarek et al. 1995) (Fridlender et al. 2009). 
 
6.6. Different tumour types have different infiltrative myeloid cells 
In a study made by Elpek and colleagues, TAM, TAN, and tumour-associated DCs 
(TADCs) were represented in all tumours but at different ratios and MDSC accumulation 
was also tumour specific. In B16 melanoma tumours, myeloid cells comprised only 40% of 
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tumour-infiltrating leukocytes compared with over 75% in 4T1 triple negative breast cancer 
and Her2+ breast cancer (Elpek et al. 2014). They also found that the percentage of TAM 
within CD45+ cells was significantly increased in Her2+ tumours (~75%) when compared 
to 4T1 (~23%) and B16 (~20%) tumours. TAN within CD45+ cells, however, were 
significantly increased in 4T1 tumours (~28%) when compared to Her2+ (~2%) and B16 
(~2%) tumours. Therefore, this and other studies propose a distinct myeloid composition 
in different tumours. Differences in tumour infiltrating myeloid cells are due to a 
combination of tumour-specified growth factors, cytokines and chemokines, suggesting 
that each tumour may create a distinctive microenvironment (Elpek et al. 2014) (Youn et 
al. 2008).  
 
6.7. Myeloid cells are anti-tumour early in tumour development and 
become pro-tumour at a later stage of tumour progression 
Myeloid cells present at early stages of tumour development have anti-tumour 
functions, delaying tumour growth. If the tumour continues growing and becomes 
established in the host, the myeloid cells are manipulated by the tumour cells and become 
pro-tumour, losing their anti-tumour capabilities (Mishalian et al. 2013) (Sagiv et al. 2015) 
(Shen et al. 2016). In diffuse large B cell lymphoma (DLBCL), TAM were reported in 
having a shift from anti-tumour to pro-tumour functions. They produced more legumain, an 
endopeptidase associated with tumour progression, in late stages of tumour development 
when compared to early stages. Thus, TAM in the late stage of tumour growth were 
associated with worst prognosis in DLBCL patients (Shen et al. 2016). 
In a model of transplantable Lewis lung carcinoma (LLC) and malignant 
mesothelioma (AB12), TAN at early stages of tumour growth are more cytotoxic, whereas 
later they acquire an immunosuppressive phenotype (Mishalian et al. 2013). The 
production of chemokines and cytokines, such as CXCL2, IL-1β, IL-10 and, interestingly, 
IL-12, were up-regulated in TAN isolated from established tumour, compared with early 
tumours. In 4T1, E0771 (triple negative breast adenocarcinoma) and AT-3 (epithelial 
prostatic carcinoma) transplantable tumours, neutrophils acquired a previously non-
existent suppressive capacity, limiting the proliferation of CD8+ T cells. This shift was due, 
in part, to the presence of TGF-β in the tumour microenvironment (Sagiv et al. 2015). 
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7. Myeloid cells can be reprogrammed to have anti-tumour functions 
In order to achieve tumour remission, most strategies targeting MC predominantly 
block their PTMc functions, rather than potentiating their anti-tumour functions. For 
instance, inhibition of PI3Kg (Kaneda et al. 2016) and blocking TGF-β, IL-10 or CSF-1R 
signalling result in decreased tumour growth (Ruffell & Coussens 2015) (Zhang et al. 
2016). However, PTMa can be reprogrammed by immunological stimuli, such as IFN-γ, 
toll like receptor ligands and cytokines into ATMa, capable of inhibiting tumour growth and 
induce T cell anti-tumour responses (Duluc et al. 2009) (Shime et al. 2012) (Biswas & 
Mantovani 2010).  
Polarized anti-tumour macrophages efficiently produce inflammatory cytokines (TNF-
α, IL-1β, IL-6) and T cell activation cytokines (IL-12) but low expression of T cell 
suppressive cytokines (IL-10) (Galdiero et al. 2013) and are able to control tumour growth. 
Many studies suggest that IL-1β promoted tumour growth and metastasis in animal and 
human breast cancer models (Guo et al. 2016) and angiogenesis (Carmi et al. 2013). 
However, in other articles, IL-1β is associated with anti-tumour effector activity produced 
by ATMa. IL-1β was reported to extend the cytotoxic state of macrophages and 
monocytes and may play a role in the defence against malignant cells, acting as an auto 
stimulating factor (Onozaki et al. 1985). Alongside IL-1β, iNOS role in tumour immunity is 
also not clear. In one hand, it was associated with malignant transformation, 
angiogenesis, and metastasis formation (Lechner et al. 2005). But on the other hand, 
iNOS production by macrophages have been reported in having cytostatic and cytotoxic 
effects on tumour cells (Stuehr & Nathan, 1989). Like PTMa, PTNe can be reprogrammed 
into ATNe through TGF-β blockade and injection of low levels of INF-β (Fridlender et al. 
2009) (Mantovani 2014). CD8+ T cell activation was increased after TAN depletion but 
after TGF-β blockage, depletion of TANs decreased CD8+ T cell activation, showing their 
anti-tumour functions (Fridlender et al. 2009). 
The reprogramming of MC in situ requires two signals, one danger signal 
provided via TLR ligands and a priming signal provided via a costimulatory agonist 
(anti-CD40).  
In a Lewis lung carcinoma transplantable model, intraperitoneal or subcutaneous 
injection of TLR3 ligand (PolyI:C) resulted in tumour regression by converting TAM into 
ATMa. TAM infiltrating the tumour respond very rapidly to TLR3 ligand and produce 
inflammatory cytokines. TNF-α was increased in the tumour and serum within 1 hour after 
injection of PolyI:C, followed by tumour necrosis and growth suppression (Shime et al. 
2012). It was also reported that mouse bone marrow- derived macrophages cultivated in 
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vitro with TLR3 ligand for 24 hours upregulated the expression of the pro-inflammatory 
cytokines TNF-a and IL-1b and the enzyme iNOS (Liu et al. 2016). This showed that 
TLR3 ligand can directly induce an anti-tumour phenotype in macrophages. 
Figure 5: Anti-tumour vaccine strategy based on TLR3 stimulation of DCs. Adapted from 
Gallois and Bhardwaj 2010. 
Other experiments showed the agonistic CD40 antibodies potential to generate 
anticancer immunity. CD40 have the ability to activate APCs and promote antitumor T cell 
responses, through activation of ATMc (Vonderheide & Glennie 2013). CD40-activated 
macrophages were reported to infiltrate tumour and have tumoricidal functions, facilitating 
control of tumour growth in a clinical trial of pancreatic ductal adenocarcinoma (PDA) and 
in a KPC mice model (spontaneously develop PDA tumours with features of human PDA) 
(Beatty et al. 2011).  
In the same line of thought, Guiducci and colleagues found that adenoviral delivery of 
CCL16, combined with the TLR9 ligand CpG and anti–IL-10 receptor antibody intra-
tumour treatment, rejected TSA mammary adenocarcinomas, MCA38 colon carcinomas, 
and 4T1 tumours. CCL16 promoted an accumulation PTMa and immature DCs in the 
tumour that, upon treatment, were converted in ATMa and mature DCs. Upon intra-tumour 
treatment, macrophages produced IL-12, TNF and iNOS and DCs secreted IFN-γ. The 
high production of TNF by macrophages induced a massive haemorrhagic tumour 
necrosis that, associated with the concomitant DCs migration to draining lymph nodes, 
primed CTLs and induced tumour eradication (Guiducci et al. 2005). 
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Despite these findings, information characterizing anti-tumour features, functions, 
phenotype and transcriptional program are critically lacking (Elpek et al. 2014). 
Consequently, this project aims at developing novel approaches to manipulate myeloid 
cells in vivo during tumour responses. The hypothesis lays on the versatility of the myeloid 
cells and that even when converted into pro-tumour subsets, MC can be “reprogramed” to 
perform anti-tumour functions. 
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Objectives 
 
To date, protocols allowing manipulation of myeloid cells in vivo are scarce, and the 
available strategies include ablation or inhibition of their pro-tumour features. However, 
studies from our laboratory demonstrate that myeloid cells can have anti-tumour 
capabilities. One of the last published articles from our laboratory, in Cancer Immunology 
Research, identified a patrolling monocyte/NK cell crosstalk induced by primary tumours 
that strongly inhibits experimental metastasis formation in the lung (Kubo et al. 2017). 
Patrolling monocytes are found to be the critical source of IL-15, an essential cytokine for 
NK cell activation and metastasis inhibition.  
Another ongoing study indicates that neutrophils could inhibit pro-tumour γδ T cell 
functions in the tumour environment, adding to the main proposal in our laboratory that 
myeloid cell populations can crosstalk with lymphocyte subsets to promote anti-cancer 
immunity. 
Our goal in this study was to manipulate myeloid cells in vivo in the tumour 
microenvironment. We planned to induce ATMc using stimulating agents, such as 
agonists of costimulatory molecules and TLR in vivo. They were be intra-tumour (IT) 
injected to act on local myeloid cells as a “reprogramming” agent, allowing the polarization 
of in situ MC into ATMc. We also assessed if the mechanism of tumour elimination is 
dependent on myeloid subsets and triggers potent anti-tumour adaptive T cell response. 
 
In this thesis, we aimed to: 
 Demonstrate that myeloid cells can have anti-tumour functions upon stimulation in 
vivo. 
 Characterize anti-tumour myeloid cell phenotype and functions. 
 Identify which myeloid cell population is capable of promoting potent anti-tumour 
immune responses, leading to tumour complete eradication in vivo. 
 Decipher which lymphocyte subsets crosstalk with anti-tumour myeloid cells and are 
capable of killing tumour cells in vivo. 
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Methods 
 
1. Mice 
C57BL/6J and BALB/c mice were purchased from Charles River Laboratories. JHT-/- 
were purchased from Instituto Gulbenkian da Ciência. Mice were kept in specific 
pathogen-free facilities at Instituto de Medicina Molecular (iMM; Lisboa, Portugal). All 
experimental procedures were performed in compliance with guidelines approved by the 
local ethics committees.  
 
2. Cell lines and tumour models. 
The E0771 and 4T1 triple negative mammary adenocarcinoma tumour cell lines were 
a kind gift from Dr. Sergio Dias (iMM), the CT26 colon cancer tumour cell line was a kind 
gift from Dr. Gonçalo Bernardes (iMM) and the B16F0 melanoma tumour cell line was 
purchased from ATCC. Tumour cells were defrosted and maintained/expanded in 
Dulbecco's Modified Eagle’s Medium (Gibco; Life Technologies), supplemented with 10% 
(v/v) of Fetal Calf Serum (FCS) (Gibco; Life Technologies) and 1% (v/v) 
penicillin/streptomycin (Sigma) (cDMEM) at 37ºC and 5%CO2. For long term storage, 
cells were ressuspended in FCS with 10% dimethyl sulfoxide (DMSO) and maintained in -
80ºC. 
 
3. In vivo tumour transplantation 
E0771 tumour cells were harvested in the exponential growth phase. After one wash 
with phosphate buffer saline (PBS) (Gibco; Life Technologies) and incubation with Triple 
Express for 3/5min at 37ºC (Gibco; Life Technologies), tumour cells were ressuspended in 
PBS at a concentration of 20x10^6 / ml. One million tumour cells were injected in the 
mammary fat pad of female C57BL/6J mice, in a volume of 50ul. Tumour volume was 
measured using a calliper and calculated as (length × width × width)/2 (mm3). To induce 
tumour regression and complete eradication, 50μg of TLR3 ligand (PolyI:C LMW) 
(1mg/ml; Invivogen; tlrl-picw) and 15μg of agonist anti-CD40 mAb (0.3mg/ml; BioXcell; 
FGK4.5) were injected IT for in vivo activation of myeloid cells. Tumour implantation and 
treatment for 4T1 tumour cell experiments were performed similarly. CT26 and B16F0 
were injected subcutaneous and only 5x10^4 cells were injected to implant B16F0 
melanoma tumours. 
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4. In vivo depletion of cell lineages 
 For depletion of neutrophils, 200μg of anti-Gr1 (1.3mg/ml; BioXcell; clone RB6-
8C5) mAb was injected IP and 50μg injected IT (0.3mg/ml) every 1, 2 or 3 days 
and always 1 day before TLR3 ligand and anti-CD40 injection. 
 For macrophage ablation, 150μg of anti-CD115 (Bio X Cell, clone AFS98) and 
200μg of clodronate-containing liposomes (Liposoma; Lip-01) were injected IV 
and 50μg of anti-CD115 and 40μg of clodronate-containing liposomes were 
injected IT every 1, 2 or 3 days and always 1 day before TLR3 ligand and anti-
CD40 injection. 
 For CD4+ and CD8+ T cell depletion, 1000μg of anti-CD4 (clone YTS169) 
(6.6mg/m) or 1000μg of anti-CD8 (clone YTA 3.1.2) (6.6mg/m) were injected IP 
once a week. Both Abs were in-house produced and kindly provided by Dr Luis 
Graca (iMM).  
 
5. Flow Cytometry analysis. 
To assess myeloid cell or CD4+ and CD8+ T cell anti-tumour effector functions, mice 
were sacrificed and tumours were resected and weighed. Tumours were collected on day 
18 (for kinetic day 2 and 3 myeloid cell experiment), on day 22 (for CD4+ and CD8+ T cell 
experiment) and on day 25 to visualize differences in tumour size between treated and 
non-treated groups after tumour implantation. Tumours were cut and digested for 30 
minutes at 37ºC with shaker at 1000 rotation per minute (rpm) in 1.5ml DMEM plus 
collagenase I (0.4mg/ml; Wortington), collagenase IV (1 mg/ml; Wortington) and DNase 
(10μg/ml; Sigma) per tissue. If tumours were enriched with erythrocytes, 500μl of RBC 
Lysis Buffer (Biolegend 420301 10x) was added after tumour digestion to osmotically lyse 
them. 
To assess myeloid cell depletion, blood samples were collected from mice facial vein 
(~ 5 drops) into Eppendorf tubes with 50μl of heparin at day 12, 18 and 24 after tumour 
transplantation. 500μl of RBC lysis (BioLegend 420301 10x) was added to each blood 
sample and Eppendorf’s were shaken for 10 minutes. This process was repeated 2 more 
times to make sure the sample was haemolysed. 
For fluorescence-activated cell sorting (FACS) analysis of tumour and blood samples, 
surface staining was done in 96 well plates. Tumour or blood cells were incubated with 
50μl of RPMI-1640 medium (Gibco; Life Technologies) supplemented with 10% (vol/vol) 
FCS, 1% (vol/vol) penicillin/streptomycin, 1% (vol/vol) and nonessential amino acids, 10 
mM HEPES, 50 uM 2-mercaptoethanol, 1% (vol/vol) pyruvate and gentamycin (10μg/mL), 
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in the presence of 2% normal mouse serum, with the antibodies presented in table 1 
(expect TNF-α, iNOS, IL-1β, IFN-γ and Foxp3),  for 1 hour at room temperature and in the 
dark. 
After surface staining, cells were treated with Zombie Violet (BioLegend) or 
LIVE/DEAD Fixable Near-IR stain to exclude dead cells, for 15min at 4ºC. 
For myeloid cell intracellular cytokine staining, tumour cells were stimulated with TLR4 
ligand (LPS from E. coli 055:B5) (1μg/ml; Invivogen;  tlrl-b5lps), IFN-γ (50ng/ml; 
Peprotech; 315-05), brefeldin-A (10μg/mL; Sigma) and 5 μM monensin (eBioscience) for 4 
hours at 37ºC. For T cell intracellular cytokine staining, cells were stimulated with phorbol 
12-myristate 13-acetate (PMA; 200 ng/mL; Sigma), ionomycin (1μg/mL; Sigma), brefeldin-
A (10 μg/mL; Sigma), and 5 μM monensin (eBioscience) for 4 h at 37 °C. For effective 
cytokine intracellular staining, cells were fixed and permeabilized using the 
Foxp3/Transcription Factor Staining Buffer set (eBioscience), following the manufacturer’s 
instructions, and incubated overnight at 4ºC in the dark with TNF-α, iNOS, IL-1β, IFN-γ 
and Foxp3 antibodies from table 1. Data was acquired on a FACS Fortessa (BD 
Bioscience) and analyzed using FACS Diva and FlowJo software (Tree Star). 
Table 1: Antibodies (clone and manufacturer) used in flow cytometry analysis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibodies Clone Manufacturer 
CD45 30-F11 Biolegend 
CD11b M1/70 Biolegend 
Ly6G 1A8 Biolegend 
SiglecF 
E50-
2440 
BD Bioscience 
F4/80 BM8 eBioscience 
Ly6C HK1.4 Biolegend 
CD11c N418 Biolegend 
IL-1β NJTEN3 eBioscience 
TNF-α 
MP6-
XT22 
eBioscience 
iNOS CXNKT eBioscience 
Antibodies Clone Manufacturer 
MHCII M5/114.15.2 Biolegend 
CD3 17A2 Biolegend 
CD4 GK1.5 Biolegend 
CD8 53-6.7 Biolegend 
IFN-γ XMG1.2 Biolegend 
PD-1 J43 eBioscience 
Lag3 C9B7W Biolegend 
Foxp3 FJK-165 eBioscience 
PD-L1 10F.9G2 Biolegend 
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6. In vitro assay 
In order to confirm that TLR3 ligand and Anti-CD40 does not affect the proliferation of 
E0771 tumour cell line we organized an in vitro assay. Five million tumour cells were 
incubated with cell track violet (CTV; 2μg/ml; Invitrogen; Clone C7001) in 1ml of PBS for 
20min at room temperature and in the dark. After incubated, cells were centrifuged at 
1000rpm for 10 minutes and washed twice with 10ml of PBS to remove all CTV outside 
cells. Tumour cells were ressuspended in cDMEM and 5x10^4 cells were distributed per 
well in a 6 well plate and incubated with TLR3 ligand (50ng/ml) plus anti-CD40 (1μg/ml) or 
IFN-γ (5ng/ml) for 72 hours. Seventy two hours later, cells were washed with 500μl of PBS 
and incubated with 500μl of Triple Express for 3/5min at 37ºC. cDMEM was added to stop 
trypsin action and cells were transferred to Eppendorfs. After one centrifugation at 
2000rpm for 8 minutes, supernatant was discarded and cells were ressuspended with 
200μl of cDMEM. FACS analysis and data was acquired on a FACS Fortessa (BD 
Bioscience) and analyzed using FACS Diva and FlowJo software (Tree Star). 
 
7. Statistical analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad Software Inc.). 
In tumour growth measurement graphs, means and standard error of mean (SEM) are 
plotted. In other graphs presented in this study, each individual value is plotted, alongside 
the means of each group, and analysed by a two-tailed unpaired t test with 95% 
confidence intervals or one-way ANOVA followed by Bonferroni's multiple comparison 
test; *P < 0.05, **P < 0.01, and ***P < 0.001 were considered to be statistically significant. 
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Results 
 
1. Intra-tumour injection of TLR3 ligand and anti-CD40 induced tumour remission 
in vivo, resulting in tumour-free long-term survival. 
Mice were transplanted with 106 E0771 breast adenocarcinoma tumour cells in the 
mammary fat pad. Tumour growth was evaluated in situ by direct measurement with a 
calliper.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: TLR3 ligand and anti-CD40 intra-tumour injection induced tumour remission, resulting 
in tumour-free long-term survival. (A) E0771 tumour growth in non-treated mice (green square; n=6) 
or mice treated (red circular; n=6). On day 12 (highlighted in the graphic), mice were injected with TLR3 
ligand plus anti-CD40 intra-tumour. (B) Tumour size and weight of mice treated with PBS and with 
ATMc-treatment (referred to as ADJ in the graph), 24 days after tumour cell implantation (C) E0771 
tumour growth in non-treated mice (green square; n=4), mice treated on day 15 (red circular with red 
outline; n=4) and mice treated on day 16 (red circular with blue outline; n=4) (D) E0771 tumour growth in 
non-treated mice (green square; n=3) or mice treated (red circular; n=7) on day 12. Mice were re-
injected on day 92 with 10^6 E0771 tumour cells. 
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When the tumour size reached 100mm3, mice were treated with an IT injection (50μl) 
of TLR3 ligand (Poly I:C) (50μg) and anti-CD40 (15μg). The treatment is supposed to 
target MC, thus will be henceforth called anti-tumour myeloid cell treatment (ATMc-
treatment). IT injection of ATMc-treatment consistently led to a dramatic reduction in the 
tumour burden and, in 90% of the cases, to the complete eradication of the tumour (Fig. 
6A). Twenty four days after tumour cell implantation, treated and non-treated mice were 
euthanized and their tumours harvested. Tumours were weighted and were significantly 
bigger in non-treated mice in comparison to the treated 12 days before tumour resection 
(Fig. 6B). As soon as 2 to 3 days after one unique injection of ATMc-treatment, there is an 
indication of tumour regression, suggesting that the MC activation occurs in the first 3 
days upon ATMc-treatment (Fig. 6C). After tumour eradication, mice received a second 
injection of 106 E0771 tumour cells on the opposite mammary gland on day 92 after the 
first tumour transplantation. The tumour cells were not able to establish a tumour mass, 
showing that the mice had an immunologic memory against E0771 tumour cells (Fig. 6D). 
 
2. TLR3 ligand and anti-CD40 did not affect the proliferation of E0771 tumour cell 
line in vitro 
In order to confirm that the effect of the treatment was not due to a direct effect on 
tumour cells, E0771 cell line was incubated with CTV to measure their proliferation using 
FACS.  
 
 
 
 
 
 
 
 
Figure 7: TLR3 ligand and anti-CD40 does not affect the proliferation of E0771 tumour 
cell line in vitro. Representative FACS plots of E0771 tumour cells incubated with TLR3 ligand and 
anti-CD40 (A) and IFN-γ (B) for 3 days. 
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Fifty thousand tumour cells were incubated with TLR3 ligand plus anti-CD40 for 3 days 
in a 6 well plate or with IFN-γ (as a positive control to know how MC-stimulators might 
affect tumour cell line proliferation in vitro (Möbus et al. 1993) (Zhao et al. 2013)). FACS 
analysis indicate that ATMc-treatment do not affect E0771 tumour cell proliferation, 
suggesting no direct impact of TLR3 ligand and anti-CD40 in E0771 tumour cell remission 
(Fig. 7A). As expected, IFN-γ affected E0771 proliferation in vitro (Fig. 7B). 
 
3. Myeloid cells accumulate in the blood during tumour progression. 
Myeloid cells can display pro-tumour features and are increased in the blood of cancer 
patients (Xu et al. 2016) (Eruslanov et al. 2012) (Gabitass et al. 2011) (Zhang et al. 2013). 
In the E0771 tumour model, the frequency of myeloid cells increased in the blood of 
tumour-bearing mice accordingly to tumour growth (Fig. 8A-B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Myeloid cells accumulate in the blood of tumour-bearing mice in later stages of tumour 
development. (A) Representative FACS plots of blood samples collected from tumour-free mice and 
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from tumour-bearing mice at day 18 and day 24 after implantation. Pre-gated on CD45+ cells, the plots 
represent the percentage of CD11b+ myeloid cells. (B) Frequencies and (C) numbers of myeloid cells 
per μl of blood volume from tumour-free mice and from tumour-bearing mice at day 18 and day 24 after 
tumour implantation. 
After day 24 of E0771 tumour cell transplantation, there was an accumulation of 
CD11b+ cells in the blood of tumour-bearing mice in comparison to the previous analysed 
day 18 after tumour implantation and to tumour-free mice (Fig. 8C). These results indicate 
a possible pro-tumour role of myeloid cells in later stages of tumour establishment. 
 
4. TLR3 ligand and anti-CD40 changed the composition of tumour-infiltrating 
myeloid cells 
To understand if TLR3 ligand and anti-CD40 IT injection was able to activate MC, 
tumours from non-treated and treated mice, day 2 and day 3 after ATMc-treatment, were 
harvested. There was an increase of the frequency of tumour infiltrating neutrophils 
(Ly6G+ cells) and a decrease in the percentage of F4/80+Ly6C+ macrophages in treated 
mice in comparison to the non-treated (Fig. 9A). The percentage of neutrophils increased 
from 11% (non-treated mice) to 60% in the tumour infiltrate of treated mice (Fig. 9A-B). 
Conversely, macrophages decreased from 81% (non-treated mice) to 33% in the treated 
mice (Fig. 9AB). The frequency of F4/80+Ly6C- macrophages did not change upon 
treatment (Fig. 9A-B). Thus, as expected, MC are affected by intra-tumour treatment with 
TLR3 ligand plus anti-CD40 mAb. 
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Figure 9: ATMc-treatment induced variations in the myeloid cell infiltrate. (A) Representative 
FACS plots of myeloid cell infiltrate in tumour harvested from non-treated mice and mice treated 2 days 
and 3 days before tumour collection. (B) Representative pie charts of myeloid cell infiltrate differences 
between non-treated and day 2 and day 3 treated mice. 
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5. TLR3 ligand and anti-CD40 decreased the frequency of PD-L1high myeloid cells 
in the tumour. 
Given that the treatment changed the composition of tumour-infiltrating MC, the 
phenotype of these cells was assessed and, in particular, the expression of a determinant 
immunosuppression marker, PD-L1. There was a reduction in the percentage of PD-
L1high expressing MC in the tumour, 2 and 3 days after ATMc-treatment injection, in 
comparison to the non-treated (Fig. 10A-C). In the tumour of non-treated mice, the 
percentage of PD-L1high MC was about 47%, whereas in the treated tumours this 
population decreased to 25% (2 days after) and 28% (3 days after) (Fig. 10A-C). The 
mean fluorescent intensity (MFI) was also lower in the MC from treated tumours 
compared to the non-treated mice (Fig. 10A-C). Thus, the treatment induced the 
downregulation of the immunosuppression marker PD-L1, showing a probable shift in the 
MC functions towards a more anti-tumour phenotype. 
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Figure 10: TLR3 ligand and anti-CD40 decreased the percentage of PD-L1high tumour infiltrating 
myeloid cells (A) Representative FACS plots from tumour of non-treated and (B) treated animals on 
day 2 and 3 of PD-L1 expression by CD11b+ cells (pre-gated on CD45+ cells) and their corresponding 
MFI, harvested on day 19 after tumour implantation (C) Graphs of the frequency of PD-L1high MC (on 
the left) and their MFI (on the right) of non-treated (green square) and treated animals on day 2 (blue 
outlined circles) and 3 (red outlined circles) after ATMc-treatment. 
 
6. Macrophages produce TNF-α, iNOS and IL-1β in response to TLR3 ligand and 
anti-CD40 treatment 
To further determine if other anti-tumour functions were acquired by MC 
simultaneously to the diminution of expression of PD-L1, changes in production of 
cytokines and enzymes, such as TNF-α, iNOS and IL-1β were assessed using FACS 
analysis. Three days after ATMc-treatment there was already a remission in the tumour of 
treated animals, suggesting that the activation of MC had already happen. Thus, anti-
tumour functions were evaluated on day 3 after treatment IT injection.  
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Figure 11: Macrophages produce iNOS upon TLR3 ligand and anti-CD40 injection. Representative 
FACS plots of non-treated (A) and treated 3 days before tumour harvest (B) on day 19 after tumour 
implantation, showing the frequency of F4/80+Ly6C- population expression of iNOS on non-treated and 
treated samples (C) Graphs displaying the frequency of iNOS by F4/80+Ly6C- cells in non-treated 
(green squares) and treated animals (blue and red outlined circles). 
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The production of iNOS was higher in the F4/80+Ly6C- macrophages infiltrating the 
tumour of treated mice when compared to non-treated (Fig. 11A-C).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: TNF-α and IL-1β double producing cells were F4/80+Ly6C+/- macrophages. 
Representative FACS plots of non-treated and treated mice 3 days before tumour harvest, on day 19 
after tumour implantation, showing the frequency of (A) TNF-α+IL-1β+ cells and (B) Ly6G+, CD11c+, 
F4/80+, Ly6C+ and MHCII+ cells from IL-1β+TNF-α+ producing cells. 
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TNF-α and IL-1β double producing cells were not neutrophils (Ly6G-) or dendritic 
cells (CD11c-) (Fig. 12A-B). Ninety percent of the double producing TNF-α and IL-1β cells 
were F4/80+Ly6C+ and 10% were F4/80+Ly6C-. Unexpectedly, the expression of MHCII 
was slightly higher in the non-treated samples in comparison to the treated. 
Therefore and accordingly to the previous results, there was an increase in the 
percentage of F4/80+Ly6C+ and F4/80Ly6C- macrophages that co-produced high levels 
of TNF-α and IL-1β in tumour of treated mice in comparison to the untreated mice (Fig. 
13A-C).  
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Figure 13: F4/80+Ly6C+/- macrophages co-produce TNF-α and IL-1β upon TLR3 ligand and anti-
CD40 injection Representative FACS plots of (A) non-treated and (B) treated 3 days before tumour 
harvest, on day 19 after tumour implantation. The frequency of F4/80+Ly6C+ and F4/80+Ly6C- 
macrophages as well as their expression of TNF-α and IL-1β on non-treated and treated samples is 
displayed (C) Graphs representing the frequency of TNF-α and IL-1β produced by F4/80+Ly6C+ (on the 
left) and F4/80Ly6C- (on the right) cells in non-treated (green squares) and treated animals (red outlined 
circles). 
 
Thus, although there was a higher increase in tumour-infiltrating neutrophil, phenotypic 
and functional changes preferentially occurred in macrophage subsets. This led to the 
assessment of the role of different myeloid lineages in tumour regression by using 
depletion strategies.  
 
7. Macrophages are required for tumour eradication, being target of TLR3 ligand 
and anti-CD40 treatment 
To understand which MC population is activated and play critical role for tumour 
rejection upon ATMc-treatment, macrophage and neutrophil populations were depleted. B 
cell role was also assessed because of their capacity to constitutively express TLR 
receptors and up-regulate CD40 ligand upon activation. For that, JHT-/- homozygote mice 
that have no mature B cells were used. Treatment induced tumour complete eradication in 
all mice lacking B cells, showing that they were not required for the treatment-induced 
tumour elimination (Fig. 14A).  
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Figure 14: Macrophages are the target of ATMc-treatment (A) E0771 tumour growth in JHT-/- mice 
(green square; n=2) or JHT-/- treated mice (orange triangle; n=5) on day 12 and 16 after tumour 
implantation. (B) E0771 tumour growth in non-treated mice (green square; n=4) or mice treated on day 
14 and 18 and depleted with anti-Gr1 on days 11, 13, 16 (red arrows) after tumour implantation (blue 
triangle; n=4). (C) E0771 tumour growth in non-treated mice (green square; n=6) or mice treated on day 
12 and depleted with anti-CD115 plus clodronate-loaded liposomes on day 9, 11, 14, 17, 19 (red arrows) 
after tumour implantation (grey triangle; n=5). 
Upon depletion of neutrophils, using anti-Gr1 (200μg) mAb injected intraperitoneal (IP) 
and IT (50μg), ATMc-treatment was still able to induce tumour complete eradication in all 
cases (Fig. 14B). By contrast, the protective effect of the treatment disappeared with the 
depletion of macrophages, using depleting anti-M-CSFR (anti-CD115 - 1mg/ml) and 
clodronate-containing liposomes, both injected intravenously (IV) (150μg and 200μg, 
respectively) and IT (50μg and 40μg, respectively) (Fig. 14C). The depletion schedule is 
described in the supplementary data (Sup Fig. 1A) and neutrophil and macrophage 
depletion was confirmed by blood analysis using FACS on the day of the first ATMc-
treatment (data not shown). These findings confirmed the crucial role of treatment-induced 
macrophages in controlling and promoting tumour eradication. 
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8. TLR3 ligand and anti-CD40 induced an increase in the frequency of CD4 and 
CD8 T cell infiltrate 
Given that TLR3 ligand plus anti-CD40 treatment induced long-lasting tumour-free 
survivors, a lymphocyte-dependent anti-tumour response was probably induced. Thus, 
phenotype and functions of tumour-infiltrating T cells were assessed in non-treated and 
treated mice. Tumours were harvested 10 days after ATMc-treatment and the percentage 
of CD4+ and CD8+ T cells was assessed (Fig. 15A-D). 
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Figure 15: TLR3 ligand and anti-CD40 induced an increase in T cell infiltrate. Representative FACS 
plots of the frequency of CD4+ T cells CD8+ T cells in (A) non-treated and (B) treated samples on day 
10 before tumour harvest. Graphs displaying the frequency of CD4+ T cells (C) and CD8+ T cells (D) 
infiltrating the tumour in non-treated (green squares) and treated mice 10 days before tumour harvest 
(red outlined circles). 
 
TLR3 ligand and anti-CD40 treatment induced an increase in CD4+ and CD8+ T cell 
infiltrate in the tumour. Tumour harvested from treated mice had more than the double in 
the frequency of tumour infiltrating CD4+ T cells and three times more in the frequency of 
CD8+ T cells (Fig. 15C-D). 
Then, regulatory Foxp3+ CD4+ T cells that carry immunosuppression in tumour 
context were specifically detected. The results clearly show a reduction in the frequency of 
Treg cells infiltrating the tumours of treated mice in comparison to the non-treated (Fig. 
16A-B).  
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Figure 16: TLR3 ligand and anti-CD40 induced a reduction in the percentage of Treg cells and 
dysfunctional CD4+ T cells infiltrating the tumour. (A) Representative FACS plots and (B) graphs of 
the frequency of Foxp3+ CD4+ Treg cells in non-treated and treated samples on day 10 before tumour 
harvest. (C) Representative FACS plots and (D) graphs of the frequency of PD-1+ CD4+ T cells in non-
treated and treated samples on day 10 before tumour harvest. In all graphs, non-treated (green squares) 
and treated (red outlined circles) animals are represented. 
 
It was further assessed weather the treatment affected the proportion of dysfunctional 
T cells. As visualised by the expression of PD-1, there was a reduction in the frequency of 
dysfunctional PD-1+ CD4+ T cells in treated mice compared to the non-treated (Fig. 16C-
D). Therefore, ATMc-treatment induced clear changes in the CD4+ T cell responses, 
promoting an increase in the frequency of CD4+ and CD8+ T cells and a decrease in 
regulatory and dysfunctional CD4+ T cells. 
 
9. TLR3 ligand and anti-CD40 induced an increase in the frequency of CD8+ T cell 
effectors and a reduction of tumour-infiltrating exhausted CD8+ T cells 
Exhaustion markers and anti-tumour functions of CD8+ T cells were similarly 
evaluated on tumours harvested on day 10 after ATMc-treatment. CD8+ T cells were 
stained against the exhausted/dysfunctional markers PD-1 and Lag-3. Tumours from 
treated mice had a decrease in frequency of infiltrating CD8+ T cells expressing both PD-
1 and Lag3 markers, when compared to CD8+ T cells from untreated mice tumours (Fig. 
17A-C).  
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Figure 17: TLR3 ligand and Anti-CD40 induced a reduction in the numbers of dysfunctional CD8 
T cells infiltrating the tumour. Representative FACS plots of the frequency of PD-1+Lag3+CD8+ T 
cells in (A) non-treated and (B) treated samples on day 10 before tumour harvest. (C) Graphs of the 
frequency of exhausted CD8+ T cells in the tumour in non-treated (green squares) and treated (red 
outlined circles) animals. 
 
To assess CD8+ T cell anti-tumour functions, cells were assessed for IFN-γ and TNF-
α production by intracellular FACS staining. Tumours from treated mice had an increase in 
frequency of CD8+ T cells capable of producing high amounts of IFN-γ and TNF-α in 
comparison to the untreated mice (Fig. 18A-C). These results from exhaustion markers 
and anti-tumour capabilities suggested that CD8+ T cells were the main effector cell 
subset leading to tumour elimination. To confirm the major role of CD8+ T cells, CD4+ and 
CD8+ T cells were independently depleted.  
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Figure 18:  TLR3 ligand and anti-CD40 induced an increase in frequency of double producing 
IFN-γ and TNFα CD8+ T cells. Representative FACS plots of the frequency of IFN-γ+TNF-α+ CD8+ T 
cells in (A) non-treated and (B) treated samples on day 10 before tumour harvest. (C) Graphs of the 
frequency of double producing IFN-γ and TNFα CD8+ T cells in the tumour of non-treated (green 
squares) and treated (red outlined circles) animals. 
 
 
10. CD8+ T cells, not CD4+ T cells, are required for tumour eradication upon TLR3 
ligand and anti-CD40 treatment 
To further identify the CD4+ T cell and/or CD8+ T cell imperative role in tumour killing, 
these lymphocytes were depleted with anti-CD4 and anti-CD8 mAbs. 1mg of anti-CD4 and 
anti-CD8 (6.67mg/ml) mAbs were injected IP once a week and ATMc-treatment was 
injected one day after the depletion. The depletion schedule is described in the 
supplementary data (Sup Fig. 1B). The findings confirm that CD8+, not CD4+ T cells, 
were responsible for tumour eradication upon treatment (Fig. 19A-B). CD4+ and CD8+ T 
cell depletion was confirmed by blood analysis using FACS on the day of the first ATMc-
treatment (data not shown).  
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Figure 19: CD8+ T cells, not CD4+ T cells, are necessary for tumour eradication upon TLR3 
ligand and anti-CD40 injection (A) E0771 tumour growth in non-treated mice (green square; n=4) or 
mice treated on days 17, 22 and 26 and depleted with anti-CD4 on days 16, 22, 30 (red arrows) after 
tumour implantation (violet triangle; n=3). (B) E0771 tumour growth in non-treated mice (green square; 
n=4) or mice treated on days 17, 22 and 26 and depleted with anti-CD8 on days 16, 22, 30 (red arrows) 
after tumour implantation (yellow triangle; n=4). 
 
Since the treatment does not induce tumour regression when CD8+ T cells were 
depleted, our data suggest that tumour eradication upon TLR3 ligand plus anti-CD40 
treatment is mediated by effector CD8+ T cells.  
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Discussion 
Our studies aimed to induce anti-tumour myeloid cells in vivo and characterize their 
features and mechanism of action(s). For that, we used maturing agents such as TLR 
ligands and costimulatory receptor agonists, known to induce MC activation. Injection of 
the ATMc-treatment directly into the tumour (when tumour volume is below 150mm3), 
consistently led to the complete remission in over 90% of treated animals. Since tumour 
regression was not obtained when macrophages and CD8+ T cell populations were 
depleted, our data suggest that tumour eradication upon TLR3 ligand plus anti-CD40 
treatment is due to a crosstalk between anti-tumour macrophages and effector CD8+ T 
cells. 
Henceforth in this discussion, we will elaborate on: 1) Experimental limitations of our 
findings; 2) Possible scenarios of action of treatment on MC that leads to CD8+ T 
lymphocyte-mediated tumour eradication; 3) Long term goal of our studies; 4) Implications 
of our findings. 
 
1. Limitations 
In the next sections we will discuss the limitations of our model and propose 
alternative approaches. 
1.1. Orthotopic model 
The in vivo results presented in this thesis were achieved using the E0771 orthotopic 
triple negative mammary adenocarcinoma model, transplanted into the mammary fat pad 
of female C57BL/6J mice. Although we were able to mimic the normal progression of 
cancer cells by injecting directly in their typical environment, our model remains poorly 
realistic. Therefore, disadvantages like the injection of genetically homogeneous cancer 
cells, the absence of elimination and equilibrium phase of cancer immunoediting and the 
rapid growth of tumour cells without chronic inflammation are present in our model 
(Eruslanov et al. 2017). However, many discoveries now used in the clinic began with 
experiments in transplantable tumour models, such as the discovery of Ab-mediated 
CTLA4 and PD-1 blockade (Harding et al. 1992) (Ishida et al. 1992). Nevertheless, 
undoubtedly oncogene-driven tumour mouse models more accurately reflect tumour 
development, being highly heterogeneous with respect to their onset, progression, 
histology and antigen expression (Zitvogel et al. 2016). 
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1.2. Calliper tumour measurement 
The measure of tumour volume in vivo is performed using a calliper and calculated as: 
(length x width x width)/2 mm3. Although this calculation gives us a 3D aspect of the 
tumour, it merely represents an approximation of the exact tumour volume present in the 
animal. The deepness of the tumour is not accessible with the calliper so it is only 
documented the visible or palpable tumour. Live animal imaging could be another option 
to accurately quantify the animal tumour burden over time. Prior to the tumour cell 
injection, tumour cells could be virally transduced to express luciferase and images of the 
tumour can be taken using a charge-coupled device camera 10min after D-luciferin 
injection. Luciferase could be a good addition in the early stages of tumour growth, 
corroborating our measurements with the calliper. However, when the tumour size is 
increasing, luciferase could not reach the interior or the necrotic areas of the tumour, 
being very unprecise (laboratory experience). 
 
 
2. Possible scenarios of ATMc-treatment action on MC, leading to CD8+ T 
lymphocyte mediated tumour eradication. 
As expected, we observed MC accumulation in the blood of tumour-bearing mice, in 
late stages of tumour progression. This is consistent with the extensively reported 
accumulation of MDSC in the circulation of cancer patients (Xu et al. 2016) (Eruslanov et 
al. 2012) (Gabitass et al. 2011) (Zhang et al. 2013). These circulating MDSC have been 
proposed to infiltrate the tumour and potentially give rise to TAN or TAM with pro-tumour 
functions (Kusmartsev et al. 2005). ATMc-treatment injected directly in the tumour 
induced an alteration in the myeloid cell infiltrate, increasing the frequency of neutrophils 
(from 10% to 50%) and decreasing the frequency of F4/80+Ly6C+ macrophages (2 and 3 
days after treatment). Using Ab-dependent depletion we ruled out neutrophils that, though 
recruited, were not essential for tumour remission. By contrast, we found that macrophage 
populations were required for the ATMc-treatment-induced tumour elimination. Therefore, 
we set out to test if ATMc-treatment induced these macrophages to acquire anti-tumour 
effector features by assessing their phenotype and functions. We found that upon IT 
injection of TLR3 ligand plus anti-CD40, the frequency of PD-L1high myeloid cells 
infiltrating the tumour of treated animals decreased compared to non-treated mice.  
In addition, although the main MC subset that accumulated in the tumour was 
neutrophils, they did not change their cytokine expression profile. Strikingly, we observed 
that two macrophage populations, CD11b+F4/80+Ly6C+ and CD11b+F4/80+Ly6C- cells, 
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produced high amounts of the anti-tumour cytokines TNF-α and IL-1β. 
CD11b+F4/80+Ly6C+ macrophages represented 90% of the double producing TNF-α and 
IL-1β cells, while CD11b+F4/80+Ly6C- cells also increased the production of the anti-
tumour enzyme iNOS. After tumour eradication, mice subjected to a second challenge of 
tumour cells did not develop tumour, suggesting the presence of an adaptive immune 
response and memory T cells that rapidly respond against E0771 tumour cells. This was 
consistent with further analysis indicating that, 10 days after treatment, the frequency of 
PD-1+Lag-3+ dysfunctional and IFN-γ+TNF-α+ effector tumour-infiltrating CD8+ T 
lymphocytes were reduced and increased, respectively. 
We will discuss how TLR3 ligand and anti-CD40 can act on responding MC subsets 
and attempt to determine: i) the pathway(s) responsible for ATMa activation and, ii) their 
potential crosstalk with IFN-γ +TNF-α+ CD8+ T effectors that would, directly or indirectly, 
promote anti-cancer immunity.  
 
2.1 TLR3 ligand signalling pathway responsible for anti-tumour macrophage 
activation. 
It is likely that TLR3 ligand plus anti-CD40 treatment is acting directly on 
macrophages that are present or infiltrating the tumour. Diverse studies suggest different 
pathways associated with TLR3 ligand signalling. Some propose that F4/80+ 
macrophages produce pro-inflammatory cytokines, including TNF-α, in a toll-like receptor 
adaptor molecule 1 (TICAM-1) dependent manner (Shime et al. 2012). Others believe that 
TLR3 ligand injection could activate the NLRP3 inflammasome in macrophages, allowing 
for the production of TNF-α and IL-1β in a TLR3 independent manner (Franchi et al. 
2014). 
In our study, it is still unclear if the expression of these cytokines is due to the TLR3 
or NLRP3 activation, the synergistic action of both or other signalling pathway(s). In the 
future, to find out the role of NLRP3 in mediating the treatment efficacy we will use an 
NLRP3 inhibitor - a small molecule MCC950 that specifically inhibits NLRP3 but not AIM2, 
NLRC4 or NLRP1 inflammasomes (Coll et al. 2015). 
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2.2 Macrophage production of TNF-α, iNOS and IL-1β can promote CD8+ T 
lymphocyte activation. 
a) By direct acting on CD8+ T cells.  
Some evidence support a direct effect of anti-tumour features of the macrophages, 
such as the production of TNF-α, iNOS and IL-1β, in CD8+ T cell activation (Fig. 20). 
TNF-α is extensively documented has being implicated in the induction of anti-tumour 
responses, being able to block the expression of M2 like genes in TAM (Kratochvill et al. 
2015) and to induce a massive haemorrhagic tumour necrosis essential for tumour 
eradication (Guiducci et al. 2005). However, TNF-α secretion and haemorrhagic necrosis 
in tumours was not enough to produce complete tumour eradication in the majority of 
tumours treated with immunotherapeutic agents (Jassar et al. 2005). A study showed that 
the use of DMXAA, a vascular disrupting molecule, efficiently activated TAM to release 
anti-tumour cytokines including TNF-α (Jassar et al. 2005). Interestingly and accordingly 
to our results, CD8+ T cells were required for anti-tumour efficacy. Finally, TNF-α was 
also described to act on multiple stromal cells to improve tumour perfusion, leukocyte 
extravasation and immune stimulation, stabilizing blood vessels and potentiating 
immunotherapy (Johansson et al. 2012). Altogether, these studies support our findings, 
showing that the activation of TNF-α producing macrophages could be crucial to generate 
CD8+ T lymphocyte anti-tumour responses. 
Alongside TNF-α, iNOS production by macrophages has been reported in having 
cytotoxic effects on tumour cells (Stuehr & Nathan, 1989). Animals treated with TLR9 
ligand plus anti-IL-10 receptor antibody had thrice more iNOS production than control 
animals (Guiducci et al. 2005). Thus, iNOS is described as an important enzyme that 
could be associated with the presence of an anti-tumour phenotype in macrophages. 
Interestingly, it was also proposed that iNOS+ macrophages are not only required but 
sufficient to mediate effector T cell recruitment into tumours, successfully inducing tumour 
rejection (Klug et al. 2013). iNOS production by macrophages, upon low-dose gamma 
irradiation, induced endothelial activation and expression of TH1 chemokines, 
suppressing the production of angiogenic, immunosuppressive, and tumour growth 
factors. 
Interestingly, IL-1β is also highly produced by macrophages in treated animals when 
compared to non-treated. However, the role of IL-1β in cancer is highly controversial as 
already described. Although mainly reported as a pro-tumour cytokine associated with 
angiogenesis promotion, IL-1β has also been shown to promote CD8+ T cell anti-tumour 
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functions (Ghiringhelli et al. 2009). In anthracycline-treated tumours, the NLRP3 
inflammasome is activated, stimulating IL-1β production and subsequently, activation of 
IFN-γ producing CD8+ T cells. In addition, one other study suggests that perforin 
production by CTLs is required for NLRP3 inflammasome activation in APCs that produce 
IL-1β, contributing to the induction of antigen-specific anti-tumour immunity (Yao et al. 
2017). This article suggests that IL-1β is the consequence of CTL activation and not the 
cause, showing a positive feedback loop of adaptive immunity to promote innate 
immunity, amplifying anti-tumour immunity. Both studies show that IL-1β production is due 
to NLRP3 inflammasome activation, potentiating the fact that TLR3 ligand could activate 
macrophages via the activation of the inflammasome. In other studies, pro-inflammatory 
cytokines have been associated with lymphocyte extravasation into tumours. IL-1β is 
associated with the activation of endothelial cells that, through the production of TNF-α-
induced protein 2, allow lymphocyte trans-endothelial migration (Barzilai et al. 2016).  
In sum, TNF-α, iNOS and IL-1β can be responsible for CD8+ T cell-mediated tumour 
eradication via several ways. This strongly suggests that ATMc-treatment induced a shift 
in TAM into ATMa. Therefore, to make sure all of them are, or which cytokine is, essential 
for the induction of tumour remission, we will assess if clodronate-liposome lead to the 
disappearance of TNF-α+ and/or iNOS+ and/or IL-1β+ macrophages, using FACS. To 
further investigate if IL-1β mediates CD8+ T cell activation, we will take advantage of IL-
1β-deficient and IL-1R-deficient mice, already in our possession, as recipients for E0771 
tumours, and subject them to ATMc-treatment.  
Figure 20: Representation of our proposed working model 
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b) By indirectly promoting CD8+ T cell activation.  
It is also plausible that macrophages are the first to respond to ATMc-treatment, 
promoting the activation of other myeloid cell subsets (Fig. 20) For instance, in our model 
ATMc-treatment induced a recruitment of neutrophils to the tumour, despite the fact tht 
TLR3 is supposedly not expressed on neutrophils (Hayashi et al. 2003). In a model of 
poxvirus infection, it was shown that TLR3 ligand induced neutrophil recruitment in the 
liver (Jenne et al. 2013). Interestingly, the depletion of macrophages, in mice deficient in 
TLR3, completely abolished neutrophil recruitment after TLR3 ligand treatment. Thus, it is 
possible that ATMc-treatment induced the activation of macrophages that, in turn, 
promoted neutrophil accumulation. We confirmed that neutrophils were not involved in 
tumour regression upon ATMc-treatment but other myeloid cell subsets could participate 
in the induction of CD8+ T cell-mediated anti-tumour response. 
DCs, for instance, could be a possible intermediate myeloid cell subset, emerging 
recently as key effector cells in priming anti-tumour T cells in the tumour (Zelenay et al. 
2015) (Ruffell et al. 2014). However, we found no difference in APC function (measure via 
MHCII expression) on macrophages and DCs between treated and non-treated animal 
tumours. Likewise, there were also no differences in tumour infiltrating DCs number, 
frequency and anti-tumour cytokine production after ATMc-treatment. However, 
macrophages could induce DC migration into the draining lymph nodes, where DCs would 
be able to perform APC functions and activate anti-tumour CD8+ T cells. Indeed, TNF-α 
production by macrophages was able to create a massive haemorrhagic tumour necrosis 
that induced DC migration to the lymph nodes for subsequent CTL priming and clearing of 
all tumour cells (Guiducci et al. 2005).  
Clodronate-containing liposomes are described to be ingested and digested by 
macrophages, followed by an intracellular release and accumulation of clodronate that 
induces their apoptosis (Van Rooijen et al. 1996). However, we can not rule out that DCs 
were not affected by the clodronate-liposomes, since they also have strong phagocytic 
capabilities. To clarify this point we will use fluorescent liposomes and assess whether 
these are up taken by DCs in the tumour and/or in the draining lymph nodes of treated 
and control animals. In parallel experiments we will assess APC functions and anti-tumour 
cytokine production by macrophages and DCs in the draining lymph nodes using FACS. 
DCs expressing CD103 have been shown to be particularly efficient at promoting anti-
tumour responses (Zelenay et al. 2015) (Ruffell et al. 2014). Thus we will also asses the 
the expression of CD103 by DCs in the tumour and draining lymph node. 
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In conclusion and as exposed above, further experiments are required to dissect the 
scenario that operates upon TLR3 ligand and anti-CD40 treatment. 
 
2.3 Other findings that could be exploited  
To determine if TLR3 ligand anti-CD40 would operate in different tumour models and 
distinct mouse backgrounds we used 3 distinct tumour models. In a transplantable colon 
cancer (CT26) tumour model in BALB/c, repetitive injections of ATMc-treatment induced 
tumour complete eradication in 2 mice, a tumour growth arrest in 2 mice, and a delay in 
tumour growth in 3 mice out of 7 treated animals (Sup Fig. 2). In a melanoma model 
(B16F0) in C57BL/6J and a triple negative breast cancer (4T1) in BALB/c, repetitive 
injections of treatment (with 2/3 days of interval) did not induce tumour remission but a 
delay in tumour growth (Sup Fig. 2). In sum, the treatment induced regression in E0771 
and in some CT26 tumours from two different mouse backgrounds, C57BL6 and BALB/c, 
respectively, but only delayed the tumour growth in B16 and 4T1 tumours.  
We believe that the different effects of TLR3 ligand and anti-CD40 combination in 
different tumour models are likely due to the different immunogenicity between the tumour 
cell lines. It is plausible that the intensity of immunosuppression in the tumour 
microenvironment varies according to the tumour type. Thus, when tumour cells induced a 
strong immunosuppressive microenvironment, the ATMc-treatment failed to convert MC to 
anti-tumour effectors, which consequently did not promote anti-tumour T cells. One way 
we found to get information about tumour cell line immunogenicity was by looking in the 
literature for the response of these tumour models to immune checkpoint therapies (Table 
2). E0771 and CT26 responded better to immune checkpoint therapy than B16F0 and 4T1 
tumour models, suggesting that they could be more efficient at inducing a host anti-tumour 
immune response. Consistent with this, MHCI background level expression was higher in 
E0771 and CT26 than B16F0 and 4T1 cell lines rendering that the first two tumour cell 
lines were more susceptible to cytotoxic CD8+ T cells. Thus, in addition to the resistance 
to ATMc-treatment, the low MHCI expression could limit CD8+ T cell recognition of B16F0 
and 4T1 tumour cells (Sup Fig. 5). These results suggest that converting MC in situ in 
poorly immunogenic cancers might reveal a difficult task to achieve.  
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Table 2: Reference search on tumour cell line immunogenicity in response to immune 
checkpoint therapy. 
 
3. Long term goal of our studies 
The first goal is to design novel ways to reprogram myeloid cells, unleashing their full 
potential as anti-tumour effector cells and CD8+ T cell activators. For that, we will assess 
if other maturing agents have the capacity to “re-program” AT macrophages and/or other 
lineages of MC effectors, particularly neutrophils. We aim at efficiently assess neutrophil 
anti-tumour functions and find out if, like macrophages, ATNe can lead to tumour 
remission upon treatment. For that, we will treat E0771 tumours with other TLR ligands 
known to be expressed by neutrophils, such as TLR2, TLR4, TLR7 and TLR9 agonists 
(Hayashi et al. 2003). Some articles report a synergy between GM-CSF and TLR2, 
showing that neutrophils enhance their expression of TLR2 and TLR9 following GM-CSF 
treatment (Hayashi et al. 2003). Therefore, we will use TLR ligands plus anti-CD40, in the 
presence or not of GM-CSF, treatment and inject directly into the tumour to induce ATNe 
in vivo and, consequently, assess their ability to promote anti-tumour responses. 
Cell lines 
Responses to 
anti-CTLA4 
therapy 
Responses 
to anti-PD-1 
therapy 
Responses to 
anti-CTLA4 + 
anti-PD-1 therapy 
References 
E0771 C57BL6 Not tested 
45% overall 
survival 
Not tested 
(Gray et al. 
2016) 
CT26 BALB/c 
60% overall 
survival 
0 - 20% 
overall 
survival 
100% overall 
survival 
(Kim et al. 
2014), (Sagiv-
Barfi et al. 
2015) 
B16 C57BL6 
0 - 25% overall 
survival 
0 - 10% 
overall 
survival 
12,5 - 45% overall 
survival 
(Curran et al. 
2010) 
4T1 BALB/c 
0% overall 
survival 
0% overall 
survival 
30% overall 
survival 
(Kim et al. 
2014), (Sagiv-
Barfi et al. 
2015) 
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The last and long-term goal is to decipher the transcriptional program that controls the 
differentiation of ATMc. By defining the transcriptional signatures associated with other 
anti-tumour MC subsets, our study may reveal novel therapeutics to target MC against 
cancer. 
 
4. Implications of our findings 
In this report we successfully demonstrated that myeloid cells can have anti-tumour 
functions upon stimulation in vivo. Upon IT injection of agonist TLR3 ligand dsRNA and 
anti-CD40 mAb, macrophages were able to produce anti-tumour cytokines and enzymes. 
We can define anti-tumour macrophages as CD11b+F4/80+Ly6C(+/-) cells that co-
produce TNF-α and IL-1β. We further propose a possible crosstalk between macrophages 
and CD8+ T cells, promoting potent anti-tumour immune responses and leading to tumour 
complete eradication in vivo. However, translation of these results into clinical applications 
is not straightforward and the promise held by TLR ligands in the clinic is still to be 
verified. Many side effects are associated with the usage of TLR, in particular TLR-
induced tolerance (Kaczanowska et al. 2013). Nevertheless, combinations of TLR ligands 
with other immunotherapeutic approaches that revolutionized treatments against cancers, 
such as immune checkpoint inhibitors, might have positive outcomes, promoting tumour 
regression and long-term survival in otherwise unresponsive patients.  
Accordingly to the data described in this thesis, a possible combination of TLR3 ligand 
plus anti-CD40 injected IT with anti-PD-1 and/or anti-PD-L1 therapy could improve CD8+ 
T cell activation. This would lead to a faster and stronger anti-tumour response, since 
these PD-1 and PD-L1 markers are upregulated in CD8+ T cells and MC from non-treated 
animals, respectively. If other TLR could target and activate other MC populations, such 
as neutrophils, a synergic affect could be exploited where not only ATMa are induced but 
also ATNe and other myeloid cell subsets. Answering these questions might help in 
designing improved immunotherapies capable of manipulating MC in a hostile 
immunosuppressive microenvironment, encouraging new studies and ways to increase 
the efficacy of anti-tumour therapy. 
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Supplementary Figures 
 
Sup Figure 1: Schematic representation of the schedule for the tumour injection (grey), ATMc-
treatment injection (blue) and depletion (red) of macrophages (top diagram) and lymphocytes 
(bottom diagram). 
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Sup Figure 2: TLR3 ligand and anti-CD40 intra-tumour injection induced tumour remission in 
CT26 and delayed the tumour growth in B16 and 4T1 tumour cells. (A) CT26 tumour growth in non-
treated mice (green square; n=3) or mice treated (red circular; n=7). On day 9, 10, 14, 16, 18, 21 
(highlighted in the graphic), mice were injected with anti-CD40 + TLR3 ligand intra-tumour. (B) B16 
tumour growth in non-treated mice (green square; n=1) or mice treated (red circular; n=2). On day 14, 
16, 18, 20 (highlighted in the graphic), mice were injected with anti-CD40 + TLR3 ligand intra-tumour. 
(C) 4T1 tumour growth in non-treated mice (green square; n=4) or mice treated (red circular; n=6). On 
day 7, 9, 12, 15 (highlighted in the graphic), mice were injected with anti-CD40 + TLR3 ligand intra-
tumour. 
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Sup Figure 3: Background level of MHCI expression on E0771, B16F0, CT26 and 4T1 tumour cell 
lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibodies Clone Manufacturer 
H-2Kb AF6.88.3 Biolegend 
H-2Kd SF1-1.1 BD Bioscience 
B16 E0771 4T1 CT26 
BALB/c C57BL/6J  
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Sup Figure 4: Flow cytometry gating strategy of (A) myeloid cell and (B) lymphocyte populations 
infiltrating the tumour. 
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